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FOREWORD 
 
Cardio & Vascular Coalition 
 
Modelling the UK burden of cardiovascular disease to 2020: A research report for the 
Cardio & Vascular Coalition and the British Heart Foundation 
 
Cardiovascular disease (CVD) is the leading cause of mortality in the UK, and was 
responsible for over 50,000 premature deaths in 2006. In recent years, much 
progress has been made to address this problem - premature death rates are down, 
surgery waiting times have been reduced, and there are more medical specialists. 
Despite these achievements, this report on the future burden of CVD highlights the 
need for continued efforts to tackle cardiovascular problems in the years to come. 
The Cardio & Vascular Coalition (CVC) commissioned this research because greater 
understanding of the future burden of CVD is essential to plan for the needs of the 
community. 
 
Led by Professor Simon Capewell, this report was produced by a joint team from the 
Universities of Liverpool, Oxford and Newcastle. The report demonstrates the scale 
of the burden of CVD - shown to be large, costly, and increasing. Whilst mortality 
from CVD has fallen, an increasing population over the next decade will create 
further demands on services as the actual numbers of people living with CVD climb 
higher. 
 
The increase in population will be especially prominent among older people, who 
represent a higher risk for CVD. At the same time, known CVD risk factors such as 
obesity, high blood pressure and Type II diabetes are increasing amongst young 
adults in the UK. This trend has worrying implications for the future incidence of CVD. 
Without further policy change, the overall burden of CVD is therefore likely to 
increase, with additional resources required for both prevention and treatment. 
 
The report’s analysis of modelling work conducted in the UK to date demonstrates 
the need to build on this study to develop and implement a comprehensive, iterative 
method for mapping the future burden of CVD. The Coalition is calling for measures 
to develop a comprehensive modelling process that will aid our ability to more 
accurately determine the future burden of CVD. 
 
The timetable of the National Service Framework for Coronary Heart Disease is 
coming to a close in 2009-2010. However, there is uncertainty over whether a new 
strategy will take its place. Yet this report demonstrates the magnitude of the future 
burden of CVD and the need to plan for the road ahead. The CVC is calling for a new 
framework to help in the long-term planning of prevention and treatment services to 
tackle CVD head on. 
 
This report will be used to inform the CVC’s Cardiovascular Health Strategy 2010 – 
2020. The Strategy will be published in early 2009, and aims to set out the Coalition’s 
proposals to tackle CVD over the next 10 years. The CVC looks forward to working 
with its partners across the community to develop plans to reduce the burden of CVD 
in the years to come. 
 
Betty McBride 
Chair, Cardio & Vascular Coalition 
 3  
 
EXECUTIVE SUMMARY  
 
 
1. THE BURDEN OF CVD IN THE UK 
 
Cardiovascular Disease (CVD) is a broad category of diseases which affect the 
heart and circulatory system. Specific CVD categories included in this report are 
coronary heart disease (CHD), heart failure and cerebrovascular disease (stroke). 
Most CVD is due to atheroma resulting in narrowing or blockage of one or more key 
arteries. The reduction of blood flow bringing essential oxygen and nutrients to an 
organ causes that organ to be damaged.  
Coronary Heart Disease (CHD) reflects a reduction of blood flow through one or 
more coronary arteries. A complete blockage obstructs the blood supply resulting in 
the death of some heart muscle (a heart attack).  
Heart failure occurs when the heart muscle's ability to pump blood is reduced.  
Stroke occurs when a blood vessel to the brain bursts or is blocked by a blood clot. 
 
Background 
• CVD remains a top policy priority in the UK and elsewhere. 
• CVD prevalence is high; over three million Britons currently suffer from CVD.   
• Annual UK costs exceed £30billion, yet 80%-90% of premature CVD is 
preventable. 
• A better understanding of the most effective interventions for reducing this large 
and costly disease burden is vital, in order to inform CVD strategies in the UK and 
elsewhere. 
 
Premature Mortality  
• Diseases of the heart and circulatory system are the leading source of 
mortality in the UK, causing almost 200,000 deaths every year.  
• About half (48%) of all deaths from CVD are from CHD and more than a 
quarter (28%) are from stroke. 
• CVD caused over 50,000 premature deaths in the UK in 2006. 
 
Morbidity 
• Heart attack and angina incidence rates increase steeply with age, and are 
higher in men than women.  
• Heart failure mainly affects older men and women, aged over 70 years.  
• Approximately 3 million Britons live with CVD problems, (some 2 million with 
angina, around 700,000 with heart failure). 
• Although CVD mortality rates have halved in the last two decades, morbidity, 
particularly in older age groups, appears to be very persistent. 
 
CVD Prevalence 
• In 2006, CVD was the second most commonly reported longstanding illness in 
the UK (after musculoskeletal conditions).  
• There are about 1,900,000 men living with CVD in the UK and about 1,400,000 
women, giving a total of approximately 3.3 million. 
 
CVD Treatment Trends 
• The cost of prescriptions for all circulatory disease is approaching £2 billion per 
annum, (over £900 million for statins and over £500 million for antihypertensive 
therapy). It is likely that costs will continue to increase in future years.  
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• Statin use (for lipid lowering) has risen steeply, being 15 times higher in 2006 
than in 1996. 
• The number of CHD inpatient cases has increased by just 13% in the last six 
years. 
• Revascularisation procedures (CABG surgery and angioplasty) have increased to 
over 80,000 per year.   
 
Economic Costs 
• The CVD burden generates huge economic consequences in the UK, both 
indirectly and directly.  The overall cost for CVD is now about £30 billion per year. 
• The impact of smoking, junk food and obesity on the national economy includes 
treating different forms of CVD as a medical problem (direct costs) and absence 
from work due to sickness, plus the burden on friends and family caring for CVD 
patients (indirect costs).   
 
International comparisons  
• CHD death rates vary tenfold between different countries. Substantial changes 
over short periods mainly reflect environmental factors rather than genetic 
factors. 
• Among more developed countries, only Ireland and Finland have a higher rate 
than the UK. 
• Death rates from CHD have been falling in the UK, but not as fast as in some 
other countries.  
 
 
2. THE COMPLEXITY OF THE CVD BURDEN 
 
CHD and CVD Data Quality and coverage 
• Information on CVD is patchy, poor and often obsolete.  Because information on 
other forms of CVD is deficient, much of this report focuses on CHD. 
• However, most of the key principles for CHD epidemiology, prevention and 
treatment also apply to CVD. 
 
Risk Factors for CVD 
• The most important modifiable factors increasing a person’s risk of future CVD 
are: smoking, elevated cholesterol, elevated blood pressure, diabetes, obesity 
and deprivation.  Numerous minor risk factors may make an additional but small 
contribution.  
 
Prevention  
• The key prevention targets are therefore tobacco control and promoting healthy 
diets.   
• Lecturing individual people has frustratingly little effect.  Much bigger gains can 
potentially come from structural policy and legislative changes at regional, 
national and international levels.   
• Primary prevention means any intervention before the first CVD event happens. 
Behaviour change (avoiding smoking and improving diet) can be complemented 
by medication for individuals at high risk of a CVD event, mainly using statins and 
anti-hypertensive therapies. 
• After CVD has manifested, secondary prevention aims to reduce the risk of 
further events (such as a heart attack, stroke, or sudden death). It includes 
healthier behaviours, like stopping smoking, Mediterranean diets, and 
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medications such as aspirin or statins. CHD patients who quit smoking reduce 
their CHD death rate by about 40% - substantially more than the reductions seen 
with statins (22%) or aspirin (15%).  
 
Social Inequalities 
• Premature death rates are up to three times higher in deprived groups than in 
affluent groups. 
• Since the 1970s, the UK death rate for CVD has fallen more slowly in manual 
workers than in non-manual workers, thus increasing the gap between these 
groups. 
• CHD and stroke are therefore key targets for reducing health inequalities. 
 
Ethnic Inequalities 
• South Asians living in the UK (Indians, Bangladeshis, Pakistanis and Sri 
Lankans), have a roughly 50% higher premature death rate from CHD. 
 
National and Regional Inequalities 
• CHD death rates and prevalence are persistently higher in Scotland, Wales and 
Northern Ireland than in South East England. These geographic variations 
suggest that large improvements in UK CHD mortality are still attainable.  
 
 
3. ESTIMATING THE CHANGING BURDEN OF CVD: 2010 TO 2020 
 
Recent Trends in CVD Burden 
• Death rates from CVD have halved in the UK since the early 1970s.   
• More than half (58%) of the CHD mortality decline in Britain during the 1980s 
and 1990s was attributable to reductions in major risk factors, principally 
smoking and, to a lesser extent, cholesterol and blood pressure. Treatments 
to individuals, including secondary prevention, explained the remaining two-
fifths (42%) of the mortality decline. 
• CHD death rates continue to fall in those aged over 55, but have recently been 
falling more slowly in younger individuals and may be rising in the youngest 
age groups. 
 
Population Estimates 
• Between 2006 and 2020 the UK population is expected to increase by 10% to 
almost 65 million, an additional 3.2 million men and 2.7 million women.  
• The older age groups will experience much larger increases in numbers.  
• CVD death rates are much higher in the oldest groups. Because of population 
ageing, the total numbers of deaths are therefore likely to increase substantially.   
• The future continuing burden of CVD will increasingly affect older groups and will 
stretch healthcare systems, even in the UK and other wealthy countries.  
• Globally, cardiovascular disease will remain the dominant cause of death and 
disability in the next few decades.   
 
Gender specific population changes 
• The male population is expected to increase by 11% between 2006 and 2020 
representing an increase of more than 3.2 million men.  
• Among men, the greatest relative population growth between 2006 and 2020 is 
expected among older age groups, specifically those aged 100 and over 
(+366%), 95-99 (+214%), 90-94 (+126%) and 85-89 (+73%). There is expected to 
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be a relative reduction in population size among those aged 40-44 (-15%) and 
those aged 20-24 (-12%). 
• Overall the female population is expected to increase by 9% between 2006 and 
2020 representing an increase of more than 2.7 million women.  
• The greatest relative population growth is expected in the older age groups, 
specifically in those aged 100 or older (+78%), 95-99 (+65%), and 90 to 94 years 
(40%).  A relative reduction in the population is expected among women aged 40 
to 44 (-16%) and 15 to 19 years (-12%)  
 
 
Recent trends in age-specific rates 
• Recent trends in age-specific rates also give cause for alarm.  In the UK and the 
USA, growing trends for obesity, diabetes, blood pressure, and metabolic 
syndrome among young adults raise concerns about increasing mortality rates 
from coronary heart disease in this group.  
• A recent examination of age-specific CHD mortality rates in the UK, using 
mortality data from 1984-2004, found age-specific CHD mortality rates for British 
adults aged 35+ years, decreased overall by -55% in men and by -48% in 
women. However, among men aged 35-44 years, CHD mortality rates in 2002 
increased for the first time in over two decades. Furthermore, the recent declines 
in CHD mortality rates appear to be slowing in both men and women aged 45-54, 
as in the USA, Australia and elsewhere.  
 
Projections to 2020 
• Large changes are expected in the next decade, particularly the ageing of the UK 
population. This will increase disease burden, since CVD incidence & mortality 
are strongly associated to age.  
• Predicted increases for CHD deaths using a conservative method indicate that up 
to 36,500 excess CHD deaths should be expected in 2020, of which 
approximately 7,300 would be premature (aged under 75 years).   
• For stroke, predicted increases for deaths using a conservative method indicate 
that up to 22,000 excess stroke deaths should be expected in 2020, of which 
approximately 2,400 would be premature (aged under 75 years).   
• In the UK, ensuring that the maximum number of eligible CHD patients receive 
appropriate medications could reduce deaths by approximately 20,000 annually. 
• Policy changes at national and international levels to achieve modest reductions 
in population cholesterol, blood pressure and smoking could result in some 
50,000 fewer CHD deaths annually. 
 
 
4. THE CHALLENGE OF PREDICTING & MINIMISING THE FUTURE CVD 
BURDEN 
 
Introduction to Modelling 
• A model is an analytical methodology that accounts for events over time and 
across populations, whose purpose is to estimate the effects of an intervention on 
health consequences and costs.   
• Successive CHD models have become increasingly robust and sophisticated.  
More recently, more comprehensive and validated models such as IMPACT and 
ARCHIMEDES have been developed. 
 
Systematic review of available models 
• We found 70 different policy models dealing with cardiovascular disease.  
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• Model quality varied considerably, with only 65% explicitly presenting 
assumptions and very few performing analyses of adequate sensitivity.  
• The majority did not provide clear descriptions of their methodology, nor provide 
access to a working version of the model to adequately judge its strengths and 
limitations.  
 
Other work currently taking place 
• The Foresight Tackling Obesities Project has gained a huge profile and 
predicts high levels of obesity in 2050.   
• The US CHD Policy Model version 3 has mainly focussed on the US population.  
• The Dutch RIVM CDM Model currently spans over 20 disease states and a 
number of major risk factors, but includes no treatments.  
• DYNAMO is an EU funded health impact assessment project which is also 
restricted to three risk factors. Results are expected in 2010.   
• The current IMPACT CHD Model has been used in many countries. It is 
calibrated for the UK population and potentially available to be updated to the 
most recent year for which data are available. 
• The new MRC funded IMPACT2 is a DES (discrete event simulation) model, 
being developed on the foundations of the original IMPACT Model.  A web-based 
version of IMPACT2 which can predict future CHD burden will be publicly 
available in late 2009. 
• The Shifting Burden of Disease Project, published by the Access Economics 
and the Australian Heart Foundation, informed this current CVC Burden project.   
• Policy models have also been developed for other diseases. 
 
What needs to be included in a large-scale modelling exercise? 
Key steps     
• Critical review and appraisal of all existing CVD models. 
• The identification and critical appraisal of a wide range of data sources. 
• The progressive development of simple models, then more comprehensive 
models.  
• Increasingly rigorous validation exercises. 
• Peer review and manuscript publication. 
• Qualitative research to elicit the views of policymakers, NHS planners and other 
stakeholders. 
 
Desirable interventions and scenarios to model 
• Models that show variations in CVD burden for the four countries of the UK and 
regions within them 
• Models which can categorise areas within countries such as PCT or Super 
Output Area (SOA) to examine regional variations in risk factors and disease 
levels.  
• Models which are capable of showing inequalities in diverse geographical areas. 
• Models which examine deprivation using local data on major risk factor levels, 
and then weight results using the most recent geographical measures of 
deprivation, such as IMD2004 or SOA. 
 
Delivering a model to predict future CVD burden 
• A satisfactory CVD modelling programme may take several years, even with 
appropriate resources. 
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Dissemination of results via heartstats.org 
• The BHF-funded web-based CHD Statistics Project provides a potentially useful 
framework to develop a rolling programme to provide future data on the burden of 
CVD. 
• Within this CHD Statistics Project, regularly collected data are used for complex 
analysis of mortality and morbidity rates and to estimate risk factor prevalence. 
• This established network of data providers is well placed to continually collect, 
collate, clean and provide data to inform models predicting the future burden of 
cardiovascular disease.  
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CONCLUSIONS & RECOMMENDATIONS  
 
 The burden of CVD is large, costly and increasing.  In the future, additional 
resources will therefore be required for CVD prevention and treatments. 
 
 Unless major changes are implemented, the CVD burden will grow during the 
next decade. 
 
 Premature CVD is eminently preventable.  However, the most effective 
interventions may require policy and legislative initiatives to support the 
current attempts to change behaviour in individuals or to medicate them. 
 
 Prediction of CVD trends to 2020 is not straightforward, because some 
factors will increase the burden, while others will decrease it.  
 
 Work to develop and compare methodologies for predicting the future CVD 
burden should therefore be commissioned. 
 
 A separate future project should aim to quantify future service requirements. 
 
 Work is also needed to develop and compare methodologies for evaluating 
the effectiveness of policy and other interventions. 
 
 A comprehensive policy model is therefore required to  
a) Make more reliable future projections and;  
b) Compare alternative future strategies. 
 
 Future models should also include analysis of the economic burden of CVD. 
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PREFACE 
 
The Cardio & Vascular Coalition (CVC) is a vibrant national coalition of 36 
voluntary organisations with an interest in promoting and protecting cardiovascular 
health.  
 
Founded in early 2007, the CVC vision is for:  
• Consistent clinical and policy leadership on best practice at national and local 
levels. 
• A Cardiovascular Health Strategy for 2010 – 2020 that joins up prevention, 
diagnosis and care from pre-birth to end of life. 
• Action to address inequalities in CVD prevention, diagnosis and care. 
• Placing CVD patients at the centre of policy and improved standards of care. 
• Close working between central government, local commissioners and the 
voluntary sector in the planning and development of CVD services and policy, 
and crucially; 
• A model to predict the future burden of cardiovascular disease (CVD). 
 
For more information on the CVC, see the website at: 
www.cardiovascularcoalition.org.uk  
 
MODELLING BURDEN OF DISEASE PROJECT ~ AIMS AND OBJECTIVES 
This report addresses a key objective of the Cardio & Vascular Coalition (CVC): 
to inform a CVD policy model to predict the future burden of disease.  
 
The project objectives are to: 
 provide comparative predictive data of UK CVD prevalence & incidence to 2020.  
 identify, analyse and critique existing models for predicting the future CVD 
burden.  
 assist the CVC and BHF to identify priorities and plan future modelling research. 
 specifically inform the CVC’s other work and objectives. 
 inform evidence-based policy development. 
 provide evidence to health and social care service commissioners for planning 
the best support for CVD patients and families.  
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This project complements the recent CVC publication CVD in England: Opportunities 
and Challenges over the next ten years, a report based principally on interviews with 
selected experts and carers and simple modelling of the future need for health care 
services (York Health Economics Consortium on behalf of CVC, 2008). 
 
The project will be completed in advance of the October 2008 release of the CVC’s 
“Green Paper” (the Consultation on a CVD Strategy for 2010 – 2020), in order to 
accord with this CVC milestone, 
 
Information on CVD is patchy, poor and often obsolete.  Because information on 
other forms of CVD is deficient, much of this report therefore focuses on Coronary 
Heart Disease (CHD). However, most of the key principles for CHD epidemiology, 
prevention and treatment also apply to CVD. 
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1.  THE BURDEN OF CVD IN THE UK 
 
CARDIOVASCULAR DISEASE MORTALITY 
 
Cardiovascular disease (CVD) remains a top policy priority in the UK, and 
elsewhere, as it causes almost 200,000 deaths every year.   
 
Diseases of the heart and circulatory system (cardiovascular disease or CVD) are 
thus the main cause of death in the UK. More than one in three deaths (35%) each 
year is from CVD.  About half (48%) of all deaths from CVD are from CHD and more 
than a quarter (28%) are from stroke (BHF Heartstats). 
 
As the dominant form of cardiovascular disease, coronary heart disease (CHD) 
causes almost 95,000 deaths in the UK every year.  CHD is thus the most common 
cause of death in the UK. Around one in five men and one in seven women die from 
the disease. CHD causes around 95,000 deaths in the UK each year. Other forms of 
heart disease cause over 30,000 deaths in the UK each year so in total there were 
some 125,000 deaths from heart disease in the UK in 2006 (BHF Heartstats). 
 
CVD mortality, incidence and prevalence rates increase steeply with age, 
approximately doubling with each decade.  CVD is rare below the age of 30, but 
increasingly common above the age of 60 (Lawlor 2002, Rothwell 2005). 
 
Furthermore, over 30,000 CHD deaths are premature (occur before the age of 75). 
Premature death rates are up to threefold higher in deprived groups than in affluent 
groups, making CHD and stroke key targets for reducing inequalities (BHF 
Heartstats). 
 
CVD prevalence is similarly inequitable, and over three million Britons currently suffer 
from CVD. Annual UK costs exceed £30 billion and NHS costs alone exceed £14 
billion and are still rising, with an additional £1 billion recently spent on NSF initiatives 
(BHF Heartstats, Luengo-Fernández 2006),  
 
Although CVD death rates may be falling at present in Westernised countries, they 
can also rise, and are rising steeply in China and many other developing countries. 
Yet, 80%-90% of premature CVD is preventable (Mwatsama 2006). 
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A better understanding of the most effective interventions for reducing this 
large and costly disease burden is thus vital, in order to inform CVD strategies 
in the UK and elsewhere, now and in the future. 
 
Information on CVD is patchy, poor and often obsolete.  Much of this report therefore 
focuses on Coronary Heart Disease (CHD), because information on other forms of 
CVD is deficient.  However, most of the key principles for CHD epidemiology, 
prevention and treatment also apply to CVD. 
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CVD DEFINITIONS 
 
Cardiovascular Disease (CVD) 
Cardiovascular disease is a general term used to describe the various presentations 
of a single underlying pathology: athero-thrombosis.  Plaques (plates) of fatty 
atheroma silently build up in different arteries during adult life. These can eventually 
cause narrowing by themselves or trigger a local thrombosis (blood clot) which 
completely blocks the blood flow, resulting in a heart attack, stroke or ischaemic leg.  
 
Most CVD is the result of reduced blood flow to the heart, brain or periphery caused 
by atheroma or thrombosis. Depending on which artery is most severely affected by 
atheroma, the main CVD manifestation can be coronary heart disease (CHD), stroke 
or peripheral arterial disease.  
 
Coronary Heart Disease (CHD) 
CHD is disease resulting from narrowing of the arteries carrying blood to the heart 
muscle. CHD includes sudden cardiac death, heart attack, unstable angina, chronic 
angina and, often, heart failure. 
 
Stroke 
This means a neurological deficit caused by ischaemia due to reduced blood flow to 
the brain. This blockage or rupture of a brain artery produces sudden catastrophic 
damage in the brain.  
The most common forms of stroke are cerebral infarct (about 80%), followed by a 
cerebral haemorrhage (about 15%).  Subarachnoid haemorrhage (SAH) accounts for 
only about 5% of strokes.  SAH is very different; it often occurs in middle aged 
patients, and the risk is increased by elevated blood pressure and a family history 
(SIGN, stroke). 
 
Peripheral Arterial Disease (PAD) 
This means a deficit caused by ischaemia due to impaired blood flow to a limb.  PAD 
most commonly affects one or both legs, causing intermittent claudication (muscle 
pain) in a calf muscle, or leg ulcers, or ischaemia/gangrene of the lower limb. Less 
commonly, but more dramatically PAD can cause an aortic aneurism. Initially hidden 
deep inside the chest or abdomen, aortic aneurisms can enlarge silently before 
suddenly leaking, often with disastrous effects. 
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Diabetes  
Diabetes means disease due to chronically elevated blood sugar levels. It is 
diagnosed on the basis of a fasting blood sugar level exceeding 7mmol/l, or 
exceeding 11mmol/l two hours after a glucose tolerance test (GTT), or on a random 
blood sample.  Milder forms may be termed “impaired glucose tolerance” (fasting 
level 6-7mmol/l, or a GTT 2 hour peak of 8-11 mmol/l). 
 
Patients experience an increased risk of developing vascular complications in large 
vessels (macrovascular complications), including CHD, Stroke. They also are at risk 
of developing retinal diseases leading to blindness and kidney failure (microvascular 
complications).   
 
Over 4% of men and 3% of women in England have diagnosed diabetes. A further 
3% of men and 1% of women aged 35 and over have undiagnosed diabetes. This 
rate increases with age to 10% of those aged 75 and over (Health Survey for 
England). We therefore estimate that there are currently just over 1.9 million adults 
with diagnosed diabetes and around 600,000 adults with undiagnosed diabetes, 
totalling around 2.5 million adults in the UK with diabetes.  
 
Diabetes substantially increases the risk of CHD. Men with non-insulin dependent 
(Type 2) diabetes have a two-fold to four-fold greater annual risk of CHD, with an 
even higher risk in women with Type 2 diabetes. The INTERHEART study suggested 
that approximately 15% of UK heart attacks are due to diabetes. 
 
Diabetes not only increases the risk of CHD but also magnifies the harmful effects of 
other CHD risk factors such as raised cholesterol levels, raised blood pressure, 
smoking or obesity.  CVD is by far the most common cause of death amongst people 
with diabetes (British Diabetic Association Cohort Study). 
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Congenital Heart Disease 
Congenital heart disease is a heart condition resulting from an abnormality in heart 
structure or function that is present at birth. Most congenital heart conditions occur 
because the heart or its valves or vessels are not properly formed. Additional defects, 
such as holes between the chambers of the heart, may be present. 
 
There are many different types of congenital heart disease. These range from simple 
defects with potentially minor consequences (for example, small ventricular septal 
defect), to complex abnormalities with serious outcomes (for example, hypoplastic 
left heart syndrome). The type and complexity of congenital heart disease depends 
on precisely how the structure and function of the heart is affected in an individual. 
 
In 2001, 810 deaths due to congenital heart disease were recorded in the UK. Just 
over a third of these deaths were in babies aged less than a year, one in seven were 
in children and adolescents (aged 1-19 years) and the remaining half were in adults 
(aged 20 years and over). Data from England and Wales show that the proportion of 
deaths from congenital heart disease occurring in babies has declined markedly over 
the last two decades. In 1986 death was most common in infancy, with just under 
60% of deaths from congenital heart disease occurring in babies aged less than a 
year. By the early 1990’s death from congenital heart disease was most common in 
adults aged 20 years and over. (Heartstats website) 
 
The precise prevalence of congenital heart malformations in the adult population is 
unknown. However, estimates can be made of the current population of adults with 
congenital heart disease in the UK, combining the known birth rate and published 
incidence and survival rates.  The British Cardiac Society Working Party on grown-up 
congenital heart disease (GUCH) recently conducted such an analysis. It estimated 
that in 2000 there were just under 150,000 adults with congenital heart disease in the 
UK. Of these, around 11,500 had the more complex forms of the disease, requiring 
life-long expert supervision and intervention. 
 
The Working Party further estimated that by the year 2010 there would be over 
185,000 adults in the UK living with congenital heart disease (over 17,000 with the 
complex forms), a rise of around 25% in simple and 50% in complex conditions since 
2000. An analysis based on data from the Northern Region Paediatric Database 
predicted an even greater growth in the numbers of adults with congenital heart 
disease over the next decade. This estimates there will be an extra 1,600 adults per 
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year in the UK, living with moderate and complex forms of congenital heart disease 
and needing long term follow up care. As a result, over the next 10 years there will be 
a significant increase in the demand for GUCH services in the UK. In the future, over 
1,600 extra adults each year will require specialist GUCH services. It is estimated 
that around 25% more consultant congenital cardiologists and surgeons are needed.
  
 
Kidney Disease 
Chronic Kidney Disease describes any irreversible damage to the kidney. Damage 
can be caused by common diseases such as high blood pressure or diabetes 
mellitus, or more rarely by diseases specifically affecting the kidneys directly. At risk 
groups include those with diabetes and cardiovascular disease, or from ethnic 
minorities. 
 
About 100 per million of the UK population reach end-stage renal failure each year 
and 600-800 per million rely on dialysis or transplant for survival. The number of 
patients is increasing by about 5% per annum. A similar number, some 1000 per 
million (0.1%) have severe kidney damage and may need renal replacement. A much 
larger number have mild kidney damage but the majority of these will never progress 
to the point where they need treatment for kidney failure. (Kidney Research UK 
website) 
 
Atrial Fibrillation  
Atrial Fibrillation (AF) is the commonest sustained cardiac arrhythmia. Patients with 
AF have a five-fold higher risk of stroke. Much of the epidemiology of AF is derived 
from data from predominantly white populations, and information on AF in non-white 
populations is scarce. Hospital practice data may give a biased view of the clinical 
epidemiology of AF, since only one-third of patients with AF may actually have been 
admitted to hospital. The prevalence of AF roughly doubles with each advancing 
decade of age, from 0.5% at age 50–59 years to almost 9% at age 80–89 years.  
(Conversely, AF is thus very uncommon in infants and children, unless concomitant 
structural or congenital heart disease is present). 
 
In the UK, the Renfrew–Paisley study found that of an original cohort of men and 
women aged 45–64 years (N=15,406) there were 100 (0.65%; 95% CI 0.53 to 
0.79%) documented cases of AF. The prevalence of AF increased with age and more 
cases were detected in men (53 of 7,052) than women (47 of 8,354).  
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In the West Birmingham AF project, the prevalence of AF was 2.4% in two general 
practices and further extension of this project showed that the prevalence of AF 
among Indo-Asians aged over 50 years in the general practice population was 0.6%.  
The Newcastle survey screened 4,843 people aged 65 years or more in general 
practices and found a prevalence of AF of 4.7%. The 4-year incidence of AF in the 
Renfrew–Paisley project was 0.54 cases per 1,000 person years.  AF is present in 3–
6% of acute medical admissions to UK hospitals. (NICE Guidance Atrial Fibrillation, 
2006).   
 
Embolic events 
Thrombi (blood clots) can form in the heart, especially in patients with Atrial 
Fibrillation. These thrombi can then travel through the circulation and obstruct blood 
flow in a crucial artery, for instance causing a stroke, or creating damage elsewhere.  
 
Heart Failure 
Heart failure is a syndrome which develops as a consequence of cardiac disease. 
Heart failure is recognised clinically by a constellation of symptoms and signs 
produced by complex circulatory and neurohormonal responses to cardiac 
dysfunction. Heart failure is a common cause of significant ill health and death in late 
middle-aged and elderly men and women in the UK. It is a serious condition with a 
poor prognosis and can markedly reduce the quality of life.  
 
A number of different UK studies of the prevalence of heart failure in the community 
have been conducted. These include the MONICA Project population in Glasgow, 
Morbidity Statistics from General Practice, Key Health Statistics from General 
Practice, and the Heart of England Screening study. From the prevalence rates 
identified in these studies we estimate there are about 390,000 men aged 45 years 
and over living in the UK with definite heart failure, and about 315,000 women, 
giving a total of around 700,000. Including cases of probable heart failure takes the 
total to approximately 900,000.  
 
The prevalence of heart failure increases steeply with age in both men and women. 
While around one in 35 people aged 65–74 years has heart failure, this increases to 
about one in 15 of those aged 75-84 years, and just over one in 7 of those aged 85 
and above. At all ages, heart failure is more common in men than women. 
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The prevalence of heart failure also varies with deprivation. Data from General 
Practitioner medical records in England show that for both men and women the 
prevalence rate of treated heart failure is lowest in the least deprived quintile of 
electoral wards and highest in the most deprived quintile of electoral wards. These 
differentials are most marked at younger ages. For example, in those aged 55-64 
years, the prevalence rates for treated heart failure in the most deprived areas in 
England are almost three times as high in women and twice as high in men, 
compared to the rates found in the least deprived areas. 
 
In 2000, just under 10,000 deaths due to heart failure were officially recorded in the 
UK. However, the number of deaths attributed to heart failure in national mortality 
statistics is likely to be a huge underestimate of the actual number of deaths caused 
by heart failure. Guidance on death certificates - that heart failure is not a cause but a 
mode of death – explicitly discourages doctors from recording heart failure as the 
underlying cause of death. This means that other causes of death, such as coronary 
heart disease, are more commonly given as the cause of death in the death 
certificates of people dying with heart failure. 
 
Combining data on incidence and survival, we estimate that the true number of 
deaths from heart failure in the UK is at least 24,000. This means at least 5% of all 
deaths in the UK are due to heart failure (Petersen 2002). 
 
 
DIAGNOSIS OF CVD 
Heart Attack (myocardial infarction): usually diagnosed from the reported medical 
history of sudden severe pain in the central chest, neck or arm. It can then be 
confirmed by an electrocardiogram (ECG) and blood tests to measure cardiac 
enzymes (including CKMB and troponin) (NICE 2001, Boersma 2003). 
Angina: usually diagnosed by the rather different history of a recurring chest pain, 
often brought on by exertion or anxiety. This can then be confirmed by doing an 
electrocardiogram (ECG) or radionuclide scan during exercise, or by an angiogram 
(X-ray of the coronary arteries) (SIGN, angina). 
Heart Failure: usually occurs in older people. It is diagnosed by the history of 
shortness of breath and fatigue. An ultrasound echocardiogram will then show the 
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reduced pumping function of the ventricles (heart muscle) and heart valves. ECG & 
blood tests (BNP) can also be useful (SIGN, heart failure). 
Stroke: usually diagnosed from the history of sudden paralysis, speech problem or 
numbness. Confirmed by a physical examination and then CT scan or MRI scan 
(SIGN, stroke). 
PAD (Peripheral Arterial Disease): usually diagnosed from a history of calf pain on 
exertion or at night, leg ulcer, or gangrene. Physical examination reveals a reduced 
blood flow confirmed by a low ankle brachial pressure index (ABPI), often followed by 
angiogram (SIGN, PAD).  
 
 
PREMATURE MORTALITY 
 
CVD is one of the main causes of premature death in the UK (death before the age 
of 75). 30% of premature deaths in men and 22% of premature deaths in women 
were from CVD in 2006. CVD caused over 50,000 premature deaths in the UK in 
2006 (BHF Heartstats). 
 
CHD by itself is the most common cause of premature death in the UK. About one 
fifth (19%) of premature deaths in men and one in ten (10%) premature deaths in 
women were from CHD. CHD caused over 30,000 premature deaths in the UK in 
2006 (BHF Heartstats). 
 
Other forms of heart disease cause more than 7,500 premature deaths in the UK 
each year. In total there were almost 40,000 premature deaths from heart disease in 
the UK in 2006 – around one fifth of all premature deaths (BHF Heartstats). 
 
Recent Trends in CVD Death Rates in the UK 
Death rates from CVD have been falling in the UK since the early 1970s.  For people 
under 75 years, they have fallen by 40% in the last ten years. Similarly, death rates 
from CHD in the UK have also been falling since the late 1970s.   For people under 
65 years, they have fallen by 45% in the last ten years (BHF Heartstats).    
 
A recent study examined the large decline in CHD mortality in England and Wales 
between 1981 and 2000. The authors concluded that more than half (58%) of that 
 21  
CHD mortality decline was attributable to reductions in major risk factors, principally 
smoking and to a lesser extent cholesterol and blood pressure. Treatments to 
individuals, including secondary prevention, explained the remaining two-fifths (42%) 
of the mortality decline (Unal et al. 2004).  
 
In recent years, CHD death rates have been falling fastest in those aged 55 and 
over. In younger age groups this decline has been slower. For example, between 
1997 and 2006 there was a 46% fall in the CHD death rate for men aged 55 to 64 in 
the UK, compared to a 22% fall in men aged 35 to 44 years. In women there was a 
53% fall in those aged 55 to 64 years and a 20% fall in those aged 35 to 44 years 
(Allender et al. 2008).  Furthermore, these rates are now beginning to plateau in 
younger age groups, as in the USA and elsewhere. (O’Flaherty 2007) 
 
Death rates from stroke fell throughout the latter part of the twentieth century.   For 
people under 65 they have fallen by 30% in the last ten years.   Recently rates have 
declined at a slower rate than previously, particularly in the younger age groups (BHF 
Heartstats).  Trends in mortality from the two main types of stroke – cerebral infarct 
and cerebral haemorrhage – are substantially different. Trends in cerebral infarct 
have mirrored those of coronary heart disease, with a rise in rates to a peak in the 
mid 1970s, and then a steady fall since (Scarborough et al. 2008). Mortality from 
cerebral haemorrhage, however, has been falling slowly but steadily since the 1940s 
(Lawlor et al. 2002).  
 
 
MORBIDITY (numbers of patients affected by cardiovascular disease) 
 
Incidence  
 
a) Myocardial infarction 
The incidence of myocardial infarction (MI) or heart attack varies geographically 
across the UK, and between men and women.  
 
The annual incidence of MI can be roughly estimated by applying the case fatality 
rates calculated by the Oxford Record Linkage Study (ORLS) to mortality data for 
the UK. Using 2006 CHD mortality data, this approach suggests that there are about 
90,000 heart attacks in men of all ages and about 60,000 in women, giving an annual 
total of approximately 150,000.  
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A more conservative estimate comes from applying the incidence rates for specific 
age groups observed in the Oxford Record Linkage Study (ORLS) to UK population 
estimates across the whole population. This procedure gives an estimate of 
approximately 65,000 heart attacks per year in all men and approximately 45,000 in 
women giving a total of approximately 110,000 heart attacks (probably an 
underestimate because heart attack rates are substantially lower in the South of 
England than elsewhere). 
 
b) Unstable Angina 
Different studies give different estimates of the incidence of angina. Using data 
from Scottish Continuous Morbidity Study, we estimate there are about 50,000 
new cases per year of unstable angina in all men living in the UK and about 
45,000 in women giving a total of about 95,000. The incidence of angina 
increases steeply with age and is higher in men than in women. 
 
c) Heart failure 
The incidence of heart failure increases even more steeply in the elderly and is 
likewise more common in men than in women. Studies of the incidence of heart 
failure are scarce and studies use different diagnostic methods. The Hillingdon Heart 
Failure Study found a crude incidence rate of 140 per 100,000 for men and 120 per 
100,000 for women. From the age-specific incidence rates we can therefore estimate 
that there are about 40,000 new cases of heart failure in men (and about 30,000 in 
women), giving a total of approximately 70,000 in the UK each year.   
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CVD PREVALENCE 
a) All cardiovascular disease 
In 2006, CVD was the second most commonly reported longstanding illness in 
Great Britain after musculoskeletal conditions (General Household Survey). 
 
The 2006 Health Survey for England suggests that about a third of elderly men 
and a quarter of elderly women had CVD (CHD or stroke diagnosed by their 
doctor). From these prevalence rates, we estimate that there are about 1,900,000 
men living with CVD in the UK and about 1,400,000 women giving a total of 
approximately 3.3 million (Table 1).  
 
Table 1. UK prevalence of CVD (CHD or Stroke) 
 
 
 
Age group (years) % Prevalence of 
CHD or stroke 
UK Population 
[1000s] 
Number with CVD 
MEN 
   
35-39 1.0 2,305.0 23,050 
40-44 1.0 2,273.8 22,738 
45-49 4.6 2,001.4 92,064 
50-54 4.6 1,815.2 83,499 
55-59 12.5 1,929.4 241,175 
60-64 12.5 1,519.0 189,875 
65-69 25.1 1,305.9 327,781 
70-74 25.1 1,083.2 271,883 
75-79 37.1 839.0 311,269 
80-84 37.1 563.6 209,096 
85+ 37.1 351.7 130,482 
Total Men 
 15,987.2 1,902,9112 
  
 
 
WOMEN 
 
 
 
35-39 0.6 2,338.2 14,029 
40-44 0.6 2,328.6 13,972 
45-49 2.1 2,040.8 42,857 
50-54 2.1 1,855.0 38,955 
55-59 5.0 1,982.3 99,115 
60-64 5.0 1,595.1 79,755 
65-69 12.6 1,405.5 177,093 
70-74 12.6 1,253.8 157,979 
75-79 27.9 1,108.1 309,160 
80-84 27.9 913.7 254,922 
85+ 27.9 824.2 229,952 
Total Women 
 17,645.3 1,417,788 
  
 
 
 
MEN & WOMEN 
  
 
3,320,700 
 24 
b) Myocardial infarction 
Prevalence of heart attack increases with age and is higher in men than in women. 
Different studies give different estimates for the prevalence of a previous heart 
attack. The most recent Health Survey for England suggests that approximately 4.0% 
of men and 2.5% of women have had a heart attack (Joint Health Survey Unit, 2008). 
 
From the combined age-specific prevalence rates, we can estimate that there are 
about 670,000 men aged between 35 and 75 living in the UK and about 180,000 
women who have had a heart attack giving a total of about 850,000.  
 
We estimate that for all people older than 35 there are about 970,000 men living in 
the UK who have had a heart attack and about 439,000 women giving a total of more 
than 1.4 million.  
 
c) Chronic Angina 
General studies on the prevalence of angina in the UK give similar rates, although 
the rate appears to be higher in Scotland than in England (Joint Health Survey Unit, 
2008; Scottish Executive, 2005).  
 
Figures from the 2006 Health Survey for England suggest that about 8% of men and 
3% of women aged 55 to 64 and about 14% of men and 8% of women aged 65 to 74 
have or have had chronic angina. From these prevalence rates we estimate that 
there are about 619,000 men aged between 55 and 75 living in the UK who have or 
have had angina and about 336,000 women giving a total of just over 955,000.  
 
Likewise, from the combined age-specific prevalence rates we estimate that there 
are about 726,000 men aged between 35 and 75 living in the UK who have had 
angina and about 393,000 women giving a total of over 1.1 million.  
 
We therefore estimate that for all people older than 35 there are about 1,132,000 
men living in the UK who have chronic angina and about 849,000 women giving a 
total of approximately 2 million.  
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d) Heart failure 
The prevalence of heart failure increases steeply with age. Around 1% of men and 
women aged less than 65 have heart failure, this increases to about 15% of those 
aged 85 and over. Studies on the prevalence of heart failure in the community give 
similar estimates of prevalence.  
 
Most recently the Heart of England Screening study (Davies et al, 2001) analysed a 
random sample of all patients aged over 45 years registered at General Practices in 
the West Midlands. They found over 2% of screened patients (3% of men and 1.7% 
of women) had definite heart failure.  Probable heart failure was seen in around a 
further 1% of patients, which suggests that more than 3% of people aged 45 and 
over in the UK have definite or probable heart failure.  
From these prevalence rates, we estimate that there are about 395,000 men aged 
45 and over living in the UK with definite heart failure, and 315,000 women, giving 
a total of approximately 710,000.  
 
Geographical variations 
Data from Key Health Statistics from General Practice on the prevalence of treated 
CHD (heart attack and angina) suggest that the prevalence of all CHD was higher in 
the North of England and in Wales than it was in the South of England, and was also 
higher in lower socio-economic groups. 
 
Temporal trends in CVD prevalence 
The surveys which have looked at morbidity trends are not consistent. Some suggest 
a fall, others a small rise. We therefore conclude that, whereas CHD mortality and 
CHD incidence are rapidly falling, CHD morbidity, particularly in older age groups, 
appears to be more persistent.  
 
The British Regional Heart Study, using a robust methodology, has reported a 
decrease in CHD prevalence.  Lampe et al. (2001) assessed whether long term 
trends in CHD event rates have influenced the burden of prevalent disease in British 
men. Their longitudinal cohort study of 7735 men, aged 40-59 at entry in1978-80, 
selected from 24 British towns. From 1978-1996, there was a clear decline in the 
prevalence of current angina symptoms: the age adjusted annual percentage change 
in odds was -1.8%. However, there was no change in the prevalence of history of 
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diagnosed CHD. Over the same period, the CHD mortality rate fell substantially 
(annual change -4.1%); rates also fell for non-fatal myocardial infarction, (-1.7%),-all 
major CHD events, (-2.5%), and first major CHD events (-2.4%).  
 
Prevalence of CHD was also measured in the 1994, 1998, 2003 and 2006 Health 
Surveys for England.  Intriguingly, between 1994 and 2006, the overall prevalence of 
self reported CHD apparently  increased slightly, from 6.0% to 6.5% in men but 
remained stable for women (from 4.1% to 4.0%). An apparent increase in the 
prevalence of CHD or stroke was also observed, increasing from 7.1% to 8.1% in 
men and from 5.2% to 5.6% in women.  The most consistent increases were found in 
the oldest groups (aged 75 years and over).   
 
Longitudinal data from the General Household Survey suggest that since 1988 there 
has been no marked change in the overall rate of self-reported morbidity from a 
previous heart attack. However, since 1988 rates of self-reported longstanding 
cardiovascular disease have increased in older age groups (by around 15% in those 
aged 65 to 74 and 48% for men and 18% for women in those aged 75 and over). 
 
Comments on stroke trends are even more problematic. Stroke mortality and 
incidence are falling substantially; prevalence is likewise probably continuing to fall.  
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CVD TREATMENT TRENDS 
 
Prescriptions 
The rapid increase in the number of prescriptions for the treatment and prevention of 
CVD in the UK shows no sign of slowing. In 2006, approximately 235 million 
prescriptions were issued for diseases of the circulatory system in England, an 
increase of 8% on 2005, and over four times as many as issued in 1986 (Office for 
National Statistics, 2008).  
 
Since 1990, the number of prescriptions for antiplatelet drugs has increased steadily, 
and there are now over 30 million prescriptions for antiplatelet drugs in England every 
year. The number of prescriptions for lipid lowering drugs (mostly statins) is now 
thirteen times higher than a decade ago, costing over £900 million per annum. 
The cost of prescriptions for antihypertensive therapy increased by 8% between 2005 
and 2006, to just over £500 million. The cost of prescriptions for all circulatory 
disease is approximately £1.9 billion per annum. Given the rapid increases in 
prescriptions for lipid lowering drugs, antiplatelets and antihypertensive therapy, it is 
likely that this cost will continue to increase in the coming years.  
 
Surgical operations and angioplasties 
Almost 29,000 operations for coronary artery bypass surgery (CABG) were carried 
out in the UK in 2003. The number of CABG procedures conducted in the UK 
increased by around a third between 1993 and 2003 before plateauing. The number 
of percutaneous coronary interventions (PCI) continued to increase to over 73,000 
annually in the UK, nearly four times more than a decade ago (British Cardiovascular 
Intervention Society, 2008).   However, rates are now falling in the USA. The number 
of angioplasties performed annually has declined by 10% to 15% since June 2006 
when results of two studies were announced, questioning the safety and efficacy of 
the procedure. 
 
Inpatient hospital cases 
In 2005/06, there were 312,165 hospital admissions for CHD, comprising 428,265 
hospital episodes (285,360 in people aged under 75), and 99,665 admissions 
(178,320 episodes) for stroke, with stroke patients occupying 20% of acute and 25% 
of long-term hospital beds. Each year in England there are approximately 110,000 
strokes, of which over 80% occur in people aged 65 and over; about 40% are 
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recurrent strokes. (Health Survey for England 2006).Stroke admissions are 
increasingly treated in specialist stroke units, involving multi-disciplinary teams 
focussed on the individual patient’s care and rehabilitation.  
 
Overall, there were around 430,000 inpatient cases treated for CHD in NHS hospitals 
in 2006/07 in England, and a further 50,000 in Scotland. These represent 
approximately 4% of all inpatient cases in men and 2% in women in England (5% and 
3% for men and women respectively in Scotland).  The number of inpatient cases 
treated for CHD has increased by over 13% in the last six years (Department of 
Health, 2008; Information Services Division, 2008). 
Medical risk factors for CHD, such as diabetes and obesity, also result in an 
additional burden to the NHS. In 2006/07 there were around 74,000 inpatient days for 
diabetes, and over 4,000 inpatient days for obesity in England (Department of Health, 
2008; Information Services Division, 2008). 
Pacemakers 
More than 40,000 pacemakers were implanted in the UK in 2006 (Network Devices 
Survey Group 2007). This represents a slight increase on the number of implants in 
previous years in England, whilst in Scotland the rate is declining slightly.  Northern 
Ireland and Wales also have a lower rate. The total national implant rate of 600 
implants per million of the population compares to a European average of 870 (with 
higher rates in France, Italy, Belgium and Germany) (Network devices survey group 
2007). 
 
NHS Staffing levels 
In 2002, a report on the provision of services for patients with heart disease in the UK 
claimed a shortage of all types of health care professionals involved in cardiovascular 
care (Hall et al, 2002). However, since then the numbers of consultant cardiologists 
and cardiothoracic surgeons have increased considerably. As of September 2005 
there were 755 cardiologists working in England, 78 in Scotland, 43 in Wales and 25 
in Northern Ireland (which equates to around 15 per million in each population). The 
number of cardiologists working in the NHS in 2005 was thus around 50% higher 
than in 1999. (Boon et al, 2006).  
 
Much of the clinical load of CVD is taken by general physicians, stroke physicians, 
diabetologists, those taking care of the elderly and those dealing with risk factors. 
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Some 255 cardiac surgeons operate in a relatively small number of centres across 
the UK. 
 
Quality of life (QOL)  
Quality of life is also a crucial issue, being particularly poor in many patients with 
heart failure or angina.  As some key interventions (such as revascularisations) 
mainly affect morbidity and quality of life rather than mortality, Quality Adjusted Life 
Years (QALYs) may represent a better measure of burden of disease in CHD. Cost-
effectiveness estimates will therefore be defined as both costs per life-year, and 
costs per QALY. Although published QALY data for CHD states was previously 
sparse, Harvard University have recently published estimates for the main CHD 
states (including stable angina and infarct survivors), which could be used in this 
proposal and for future work (Harvard QOL website). 
 
Reduction in QOL may be even more marked in stroke survivors.  Furthermore, 
individuals with hypertension, hyperlipidaemia, obesity or diabetes mellitus may also 
experience illness behaviour.  
 
ECONOMIC COSTS OF CVD 
 
The CVD burden has considerable economic consequences in the UK both directly 
and indirectly. The impact of smoking, junk food and obesity on the national economy 
includes treating different forms of CVD as a medical problem (direct cost) and 
absence from work due to sickness, or the burden on friends and family caring for 
CVD patients (indirect cost).  The overall cost estimate for CVD now exceeds £30 
billion per year (Allender et al. 2008). 
 
Direct costs of CVD 
The cost of treating CVD was estimated at £14.3 billion per year in the UK in 2006 
(Allender et al, 2008). These costs include NHS consultations, diagnostic tests and 
treatments for diseases related to CVD, such as CHD, stroke & PAD. The direct 
costs of treating CVD represent about 20 % of the NHS expenditure.  Additional 
costs arise in detecting and treating people with an increased risk of CVD because of 
smoking, hypertension, hyperlipidaemia, diabetes or obesity.  
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Statin use 
Statin use has risen exponentially since the early the 1990s. The volume of 
prescribing has increased by 150% in the last 5 years and the cost to the NHS was 
approximately £600m in 2005 (National Electronic Library for Medicines 2007). NICE 
guidance on the use of statins was published in 2006 (NICE 2006).  
Similar rises have recently been seen for obesity drugs and newer antihypertensives. 
Following the publication of the CHD NSF in 2000 (DoH 2000), the number of 
revascularisation procedures (CABG surgery and angioplasty) also increased 
dramatically, from 494 per million population in 1999 to 894 by 2003. Costs in 2004 
totalled approximately £1billion (Swanton 2006). 
Indirect costs of CVD 
The indirect cost of CVD was estimated at around £16.2 billion per year in the UK in 
2006. These costs take into account informal care (£8.0 billion) and lost productivity 
as a result of CVD and CVD-related illnesses, and the deaths of affected workers 
(£8.2 billion) (Allender et al, 2008).  
 
 
INTERNATIONAL COMPARISONS 
 
CHD death rates vary tenfold between different countries.  Death rates are twofold 
higher in the former USSR republics compared with the UK, Netherlands and 
Germany. These in turn are up to fivefold higher than France, Southern Italy, Japan 
and China. These substantial geographic differences, along with the large changes 
seen in migrants from low-rate to high-rate countries, plus the large changes in CHD 
mortality rates over short periods emphasise the importance of environmental rather 
than genetic factors. 
 
International CVD trends 
While the mortality rate from CHD has been falling in the UK it has not been falling as 
fast as in some other countries. For example the death rate for men aged 35 to 74 
fell by 42% between 1990 and 2000 in the UK, but it fell by 48% in Australia and 54% 
in Norway. For women, the death rate fell by 44% in the UK, but in Australia and New 
Zealand the rate fell by 51% and 48% respectively (Allender et al, 2008b). 
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2.  THE COMPLEXITY OF CVD AS A DISEASE BURDEN 
 
The main causes of CVD have been understood for over half a century. Effective 
advice was already possible when the Finland North Karelia Project was designed in 
1970 (Laatikainen 2005).  
 
RISK FACTORS FOR CVD 
 
Fixed Risk Factors 
Age 
CVD mortality, incidence and prevalence rates all increase steeply with age, 
approximately doubling with each decade. CVD is thus increasingly common above 
the age of 60 but rare below the age of 30. 
Male sex   
Men tend to get CHD about ten years younger than women.  
 
Modifiable Risk Factors 
Cholesterol and dietary saturated fats (animal & dairy)  
Cholesterol is the most powerful and important risk factor for CHD and other forms of 
athero-thrombotic CVD. Some thirty years ago, Geoffrey Rose observed that 
cholesterol was necessary for CHD, but not sufficient (Rose 2004). That still remains 
true today. CHD risk increases logarithmically from about 3.5mmol/l total cholesterol 
(TC) (Law 1994). With a UK mean of approximately 5.4mmol/l, almost every adult 
therefore has a higher than ideal level of TC.  “Target TC levels of “5.0”, 5.2” etc are 
thus relatively arbitrary. 
Total Cholesterol is made up of lipid sub-fractions: about 2/3 LDL (low density 
lipoproteins), 1/6 HDL (high density lipoprotein) and 1/6 triglycerides. CHD risk is 
increased by higher LDL levels, but reduced by higher levels of (protective) HDL.   
Total cholesterol levels below 4 mmol/l were seen in some nomadic and pastoral 
communities, including rural populations eating a traditional Chinese diet (Chen 
1991, Law 2003). However, TC rises with Westernisation of the diet, the main culprit 
being increased consumption of animal and dairy fats. These contain saturated fatty 
acids (“Bad fats”, which increase CHD risk).  Conversely, vegetable fats and oils and 
fish provide mono- and polyunsaturated fatty acids which lower TC and LDL, and 
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increase the HDL/LDL ratio (“good fats”, which decrease CHD risk) (Mwatsama 
2006; Jenkins 2006). 
 
Blood pressure and dietary salt  
CHD risk increases logarithmically from a diastolic blood pressure of about 70mmHg 
(or an equivalent systolic blood pressure of about 115 mmHg). In 2006, 
approximately 30% of UK adults had a blood pressure exceeding 140/90 (HSE) while 
almost 100% had a higher than ideal level of blood pressure. Defining “hypertension” 
as a blood pressure above 140/95 or 120/80 mmHg is thus relatively arbitrary. 
 
Blood pressure in populations powerfully reflects average dietary intake of salt.  In 
traditional communities which consume little salt, low blood pressure remains the 
norm into old age. Conversely, blood pressure rises with age in all industrialised 
populations, with Western diets typically involving about five times as much daily salt 
intake as biologically necessary.  Happily, long-term or even short-term reduction in 
dietary salt intake reduces blood pressure in individual subjects (HE 2003). 
Blood pressure is also increased by dietary saturated fats, but decreased by 
sustained weight loss or regular physical activity.   
Blood pressure is also a powerful risk factor for stroke, especially hemorrhagic forms.  
Smoking  
Compared with non-smokers, CHD rates are about five times higher in young adult 
smokers, and about twice as high even in older smokers. Happily, this increased 
CHD risk halves within a year of quitting and becomes minimal after a decade (Doll 
2004, Critchley 2003). Smoking is also a major risk factor for stroke, and even more 
so for PAD.  
 
Diabetes (and impaired glucose tolerance)  
About 80% of diabetics die from CHD. CHD rates are thus 2-3 times higher in 
diabetics, and increase with the duration of the disease. CVD risk also increases with 
pre-diabetes/glucose intolerance or insulin resistance. The risk of type 2 diabetes is 
greatly increased by obesity. 
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Obesity   
Obesity increases the risk of subsequent CHD by 25%-50% depending on its 
duration and severity (Stamler 2004). Obesity quantified as a raised Body Mass 
Index (BMI) or increased waist circumference represents an “upstream” risk factor for 
CVD.  In other words, obesity does not cause most of its cardiovascular damage 
directly, but indirectly by chronically increasing blood pressure, cholesterol and 
glucose levels. The overall contribution is substantial (Yusuf et al. 2005). Today’s UK 
environment is “obesogenic”, being dominated by powerful commercial and social 
forces marketing bounteous sources of cheap saturated fat; all made worse by 
multiple barriers to routine physical activity (Jain 2005). 
 
Physical inactivity  
CHD rates are apparently twice as high in sedentary groups as in those who are 
physically active. Sedentary people also tend to smoke more and have higher BP, 
cholesterol and weight. Thus, considering exercise by itself, successfully changing 
from a sedentary lifestyle to an active lifestyle long term can reduce CHD risk by 
about 30% (Emberson 2005). Sadly, the current UK environment promotes sedentary 
lifestyles and generates many barriers to routine activities like walking or cycling. 
   
Major and minor risk factors for CVD 
The InterHEART study recently reported that nine factors explain over 90% of heart 
attacks (those discussed above and also excess alcohol, a diet low in fruit and 
vegetables and “psycho-social” factors) (Yusuf 2004). 
The BRHS recently emphasized that the three major risk factors, Total Cholesterol, 
Blood pressure and Smoking together explain 80%-90% of CHD in the UK 
(Emberson 2003). Although epidemiologists and geneticists are researching new 
factors, (such as homocysteine, CRP, ACE gene expression etc), none will ever be 
considered “major” risk factors (Emberson 2003, Stamler 2004). 
Risk factors for hemorrhagic stroke & peripheral arterial disease (PAD)  
Risk factors for these CVD conditions resemble those for CHD. However, 
haemorrhagic stroke rates particularly reflect levels of blood pressure (systolic more 
than diastolic).  PAD risk factors likewise reflect the major CVD risk factors, but 
especially smoking.  
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PREVENTION 
 
Primary Prevention 
This means doing something early, as opposed to after the silent CVD has already 
emerged as a heart attack or stroke. The key prevention targets for behaviour 
change are promoting healthy diets and tobacco control.  Much effort has been 
traditionally expended lecturing individual patients, to little effect (Smith & Ebrahim, 
1997 and 2006). Thus, in the USA, after two decades of individual- focused health 
education encouraging citizens to “know their number”, total cholesterol levels in the 
USA fell by just 0.3mmol/l, less than in most comparable countries (Carroll 2006).   
 
The conventional medical approach is to identify and then treat high-risk individuals. 
High-risk is currently defined as a five year risk of a CVD event exceeding 20%. The 
mainstay therapies are long-term statins and anti-hypertensive medication.  Details 
are provided by clinical guidelines from the UK, Europe and USA.  Although 
orthodox, the value of this approach remains unclear (Capewell 2008). 
 
Conversely, much bigger gains can potentially come from structural policy changes 
at regional, national or international levels.  Simple things can work well.  For 
instance, in Finland, where policy changes included legislation and subsidies for 
berry farmers, population total cholesterol (TC) levels fell by more than 1.0 mmol/l in 
fifteen years (Laatikainen 2005).  Dramatic 0.8 mmol/l falls in TC were seen in the 
Mauritius population following legislation to promote healthier (vegetable) cooking 
oils (Dowse 1995).  Conversely, in Europe, harmful EU Common Agricultural Policy 
(CAP)-related subsidies annually purchase 1.5Kg of saturated fat in whole milk for 
every school child and 1.5 Kg of butter for every adult (Elinder 2003).  The CAP thus 
raises cholesterol, causing at least ten thousand additional CVD deaths every year 
(Lloyd-Williams et al. 2008). 
 
Likewise for tobacco control, smoking prevalence is most effectively reduced by 
taxation, price increases and legislation such as advertising bans and smokefree 
legislation, not by lectures to individuals (Chapman 1996).  
Prevention at a population level requires co-ordination. In the UK, the national level is 
addressed by the National Heart Forum (NHF). The NHF was established in 1984 as 
an "active authoritative body at the national level to speak out for policies directed at 
 35  
the prevention of CHD" and to maximise the contributions of not-for-profit sector 
organisations. Since its launch, the NHF has been instrumental in driving the national 
CHD prevention policy agenda, developing consensus and evidence-based 
recommendations for action across a diverse range of issues and settings and co-
ordinating advocacy for their implementation. The National Heart Forum's mission is 
to work with and through their members to contribute to the prevention of avoidable 
coronary heart disease and related conditions in the UK. 
Regional programmes also energetically address prevention, such as Heart of 
Mersey (HoM). HoM was launched as a non-governmental organisation in 2003 and 
became a registered charity in 2005. HoM is an excellent working example of a 
regional health regeneration partnership. HoM aims to add value to local initiatives 
and programmes by working at local, regional, national and European levels to 
prevent CVD in the population through integrated, evidence-based interventions. The 
programme targets the major risk factors associated with achieving these aims, 
mainly poor diet (dietary fat, salt and sugar), and smoking (including second-hand 
smoke). 
 
Secondary prevention 
This means prevention of further events after CVD has manifested as a heart attack 
or stroke. It includes healthier behaviours, like stopping smoking, and medications, 
such as aspirin or statins. 
 
Median survival after a first AMI or stroke averages barely 8 years (Capewell et al, 
2000). The benefits of even the most powerful interventions will thus be frustratingly 
limited. 
 
CHD patients who quit smoking reduce their CHD death rates by about 40% 
(Critchley 2003). Adopting a Mediterranean or fishy diet has similar benefits (de 
Lorgeril 2006).  An exercise-based rehabilitation programme may reduce mortality by 
almost 30% (Taylor 2006).  
 
Secondary prevention medications, if taken long-term, also reduce subsequent 
mortality by approximately 15% (aspirin), 20% (ACE inhibitors), 22% (statins), 22% 
(warfarin), and 23% (beta-blockers) (Ford 2007). 
 36 
The various lifestyle changes and medication benefits are assumed to cumulate 
additively. However, that is uncertain; randomised controlled trial (RCT) evidence is 
very difficult to obtain (Yusuf 2002). 
 
Sudden Deaths 
Over 70% of CHD deaths occur outside hospital; many are sudden cardiac deaths, 
occurring less than an hour after the first symptom, often in people alone at the time.  
Opportunities for medical intervention are thus frustratingly small, making primary 
prevention even more important (Capewell et al, 2001). 
 
SOCIAL INEQUALITIES 
 
In England and Wales there is a strong positive relationship between deaths from 
circulatory diseases and levels of deprivation. This pattern is clear in CHD and stroke 
for both men and women (Romeri et al. 2006).  
 
Since the 1970s in the UK the premature death rate from CHD has fallen across all 
social groups for both men and women. However, the death rate for men has fallen 
faster in non-manual workers than in manual workers, and the difference in death 
rates has increased between these groups (Office for National Statistics, 2003).  
 
To help reduce these socio-economic inequalities, CVD inequalities targets have 
been introduced in England, Scotland and Wales. Data from the Central Health 
Monitoring Unit show that in England there has been some progress towards this 
target: the absolute gap in CVD mortality between the fifth most deprived areas and 
the population as a whole, in people aged less than 75 has fallen by approximately 
20% since the mid-1990s (Allender et al. 2008). 
 
ETHNIC INEQUALITIES 
 
Mortality rates for CHD and stroke vary by ethnic group in the UK.  Premature death 
rates from CHD for men born in the Caribbean and West Africa and for women born 
in Italy but living in the UK were lower than average.  
 
However, there is a higher premature death rate from CHD than average among men 
and women living in the UK but born in South Asia and Eastern Europe. In 2003, the 
 37  
death rate among Bangladeshi men was 112% higher and the death rate among 
Pakistani women living in England was 146% higher than the average for England 
and Wales. Men living in England but born in Bangladesh have more than twice the 
average chance of suffering premature death from stroke. Women born in Jamaica 
and living in England were 76% more likely to die prematurely from stroke than those 
born in England and Wales (Harding et al, 2008).  
 
The difference in the death rates between those born in South Asia and the general 
population increased in the 1970s and 1980s.  This is because the death rate from 
CHD was not falling as fast in South Asian groups as it was in the rest of the 
population.  For example, from 1971 to 1991, the CHD mortality rate for 20 to 70 year 
olds for the whole population fell by 29% for men and 17% for women, whereas in 
people born in South Asia it fell by only 20% for men and 7% for women (McKeigue 
et al, 1997). Furthermore, inequalities in mortality rates between the general 
population and South Asians are continuing to increase (Harding et al. 2008). 
 
 
NATIONAL AND REGIONAL INEQUALITIES 
 
Mortality 
For over 25 years, CHD death rates have been consistently higher in Scotland, 
Wales and Northern Ireland when compared to England.  
 
Among men aged 35 to 74 years, the rate of CHD death in 2005 was 161 per 
100,000 population across the United Kingdom. Rates were highest in Scotland 
(213), intermediate in Wales (179) and Northern Ireland (175) and lowest in England 
(155). The premature death rate for men living in Scotland was 70% higher than in 
the South West of England. Likewise amongst women aged 35 to 74 years, the CHD 
death rate was 52 per 100,000 in the United Kingdom.  Differences in national rates 
were similar to men; highest in Scotland (75), intermediate in Northern Ireland (60) 
and Wales (59) and lowest in England (49). The premature death rates for women 
living in Scotland were 88% higher than in South West England (Scarborough et al. 
2008). 
 
Furthermore, there is considerable variation in mortality rates within regions and 
countries of the UK.  For example, male all-ages CHD mortality rates for local 
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authorities in Scotland range from 139 per 100,000 in East Dunbartonshire to 262 per 
100,000 in Inverclyde: a difference of 88%. Female all-ages mortality rates in 
Northern Ireland range from 71 per 100,000 in North Down to 109 per 100,000 in 
Derry: a difference of 55%. 
 
The pattern of higher rates of CHD mortality in Northern areas of England, and in 
Scotland, Wales and Northern Ireland remains evident at local levels. For male 
premature CHD mortality rates in the UK, only 6% of wards in the South West and 
South East of England are in the highest quintile (i.e. top 20%), compared with 32% 
in the North East and North West, and over 40% in Scotland. The pattern is very 
similar for women (Scarborough et al. 2008). 
 
Explanations of these geographical gradients are complex, but are partly attributable 
to regional inequalities in the major CVD risk factors, particularly smoking, diet and 
deprivation. 
 
The geographic variations in CHD mortality rates suggest that dramatic 
improvements in CHD mortality in the UK are still attainable. For example, if every 
local authority in the UK had the same CHD mortality rate as Kensington and 
Chelsea, then there would be approximately 32,500 fewer deaths every year in 
England, almost 5,500 fewer deaths in Scotland, 3,000 fewer deaths in Wales and 
1,300 fewer deaths in Northern Ireland; a total of over 42,000 fewer deaths in the 
United Kingdom, (including 15,000 fewer premature deaths before the age of 75 
(Scarborough et al, 2008). 
 
Morbidity 
There is also some geographic variation in CVD prevalence rates. The Health Survey 
for England 2003 suggested that in men, one in five in Yorkshire and the Humber 
(20%) and the West Midlands (19%) report ever having some form of diagnosed 
CVD compared to 15% of men in the South West and 16% in London and the East of 
England. Furthermore, the prevalence of CHD in men is nearly twice as high in 
Yorkshire and the Humber (12%) than in the South West (7%) and East (7%) of 
England.   
 
Correspondingly, CVD prevalence rates for women range from 14% in London to 
20% in the West Midlands. CHD varies even more dramatically; only 4% of women in 
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the South West and East of England report a doctor diagnosis of CHD compared with 
10% of women in the North East (Department of Health, 2004). 
 
Regional differences at a local level: Hospital activity 
Geographic variations in CHD hospitalisations are not as clear as those for mortality, 
probably because supply-side factors and variations in demand may obscure the true 
underlying need (Stevens & Raftery 1999). For example, hospitalisation rates tend to 
be higher in the North than the South of England, but higher rates also tend to be 
found in urban areas. Over 27% of the wards in London are in the top quintile (i.e. top 
20%) of hospitalisation rates for male under 75s in England. This rises to 35% for 
wards in the North East, and is as low as 9% for wards in the South East. For women 
of all ages this range is even larger: 44% of wards in the North East are among the 
top quintile for female hospitalisation rates compared to only 7% of wards in the 
South East (Scarborough et al, 2008).  
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3.  ESTIMATING THE CHANGING BURDEN OF CVD to 2020 
 
Future projections require consideration of trends in three separate components: 
populations, disease rates and potential interventions. 
  
POPULATION ESTIMATES 
 
The UK Office for National Statistics regularly provides population projections by age 
and sex for the United Kingdom and constituent countries. The main focus of the 
2006-based projections are for the next 25 years. Variant projections based on 
alternative assumptions of future fertility, mortality and migration are also available.  
 
Figure 1 shows that between 2006 and 2020 the UK population is expected to 
increase by 10%, from just under 59 million to almost 65 million.  In crude terms, 
the population is thus predicted to increase by almost 6 million people between 2006 
and 2020. The biggest numerical increases in population are anticipated in middle 
age and beyond: 940,000 among those aged 70-74, 550,000 (65-69 years), 825,000 
(50-54 years), 760,000 (30-34 years) and 725,000 in those aged 25-29 years.  Small 
population decreases are expected in the younger age groups aged 40-44 (-
700,000), 35-39 (95,000), 20-24 (45,000), and 15-19 (-455,000). 
 
Examining population projections in five year age bands shows that the older age 
groups will also experience the largest proportional increases in population. The 
specific age groups experiencing the greatest increase are those aged one hundred 
and above (+114%), 95-99 (+94%), 90-94 (+63%), 70-74 (+41%) and 80-84 years 
(+25%).  Conversely, reductions in population are expected among younger age 
groups including those aged 40-44 (-15%), 15-19 (-12%), 35-39 (-2%) and 20-24 
years (-1%). 
 
GENDER-SPECIFIC POPULATION CHANGES 
 
Men  
Overall the male population is expected to increase by 11% between 2006 and 2020, 
representing an increase of more than 3.2 million men.  The greatest relative 
population growth between 2006 and 2020 is expected among older age groups, 
specifically those aged 100 and over (+366%), 95-99 (+214%), 90-94 (+126%) and 
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85-89 years (+73%). There is expected to be a relative reduction in population size 
among those aged 40-44 (-15%) and those aged 20-24 years (-12%). In terms of 
actual numbers, it is expected that there will be 3.2 million more men in 2020 than in 
2006. This includes 470,000 more men aged 70 to 74, 405,000 aged 50 to 54 and 
425,000 aged 30 to 34.  Population reductions are predicted among men aged 40 to 
44 (-335,000) and 15 to 19 years (-235,000). 
 
Women 
Overall the female population is expected to increase by 9% between 2006 and 
2020, representing an increase of more than 2.7 million women. The greatest relative 
population growth is expected in the older age groups, specifically in those aged 100 
or older (+78%), 95-99 (+65%), and 90 to 94 years (40%).  A relative reduction in the 
population is expected among women aged 40 to 44 (-16%) and 15 to 19 years (-
12%) In terms of actual numbers, it is expected that there will be 2.8 million more 
women in 2020 than in 2006. This includes 470,000 more women aged 70 to 74 and 
420,000 aged 50 to 54 years.  Population reductions are predicted among women 
aged 40 to 44 (-365,000) and 15 to 19 years (-220,000) (Figure 1). 
 
 
Figure 1: Population projections by the Office for National Statistics Great 
Britain (2006-based)  
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RECENT TRENDS IN AGE-SPECIFIC RATES 
 
Recent trends in age-specific rates also give cause for alarm. In the UK and the USA, 
trends for obesity, diabetes, blood pressure, and metabolic syndrome among young 
adults raise concerns about the CHD mortality rates in this group.  
 
A recent examination of age-specific CHD mortality rates in the USA, using mortality 
data from 1980-2002 to calculate age-specific mortality rates from CHD for adults 
aged ≥35 years found the age-adjusted mortality rate decreased by 52% in men and 
49% in women. Among women aged 35-54 years, the estimated annual percentage 
change (EAPC) in mortality was -5.4% from 1980 until 1989, -1.2% from 1989 until 
2000, and plus 1.5% from 2000 until 2002. Among men aged 35-54 years, the EAPC 
in mortality was -6.2% from 1980 until 1989, -2.3% from 1989 until 2000, and just -
0.5% from 2000 until 2002. Among women and men aged ≥55 years, the estimated 
annual percentage decrease in CHD mortality continued (Ford & Capewell 2007). 
 
Recent UK population rates were worryingly similar. Between 1984 and 2004, age-
specific CHD mortality rates for British adults aged ≥35 years decreased overall by -
55% in men and by -48% in women. Among older adults, mortality rates continued to 
decrease steadily throughout the period. However, among men aged 35-44 years, 
CHD mortality rates in 2002 increased for the first time in over two decades. 
Furthermore, the recent declines in CHD mortality rates appear to be slowing in both 
men and women aged 45-54. (O’Flaherty 2007; Allender 2007). 
 
These trends in CHD mortality rates among younger adults in the UK and USA may 
serve as a sentinel event. Deterioration in medical management of CHD appears 
implausible.  Thus, unfavourable trends in cardiovascular risk factors provide the 
most likely explanation for the observed trends (Ford & Capewell 2007; OFlaherty 
2007; Allender 2007). 
 
New treatments look exciting, but the population impact appears less clear  
A large number of evidence-based cardiological treatments reduce coronary deaths 
in randomised trials.  However, the CHD National Service Framework (NSF) 
recognised that many eligible patients fail to receive effective treatments. We 
therefore used the IMPACT Model to examine the potentially achievable coronary 
mortality reduction through increased treatment levels in England and Wales. 
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In 2000, medical and surgical treatment levels in England and Wales were generally 
poor; only 30% - 60% of eligible patients received appropriate therapies. These 
treatments together prevented or postponed approximately 25,800 deaths.  
Increasing treatment levels to reach 80% of eligible patients (the NSF target) would 
have prevented or postponed approximately 20,900 further deaths (minimum 
estimate 11,000, maximum estimate 33,500): approximately 35% coming from 
increases in heart failure therapies, 23% from secondary prevention therapies, 16% 
from the primary prevention with statins, 11% from acute myocardial infarction 
treatments, 7% from treatment of angina and just 2% from an 80% increase in the 
number of revascularisation procedures. 
 
We concluded that increasing the proportion of eligible CHD patients receiving 
appropriate treatments could have prevented or postponed over 20,000 further 
deaths in England and Wales in 2000.  However, this still looked rather modest and 
costly compared with the 50,000 fewer deaths potentially achievable by small and 
eminently feasible additional reductions in population cholesterol and blood pressure 
(Capewell et al 2007, Unal et al 2006). 
 
 
PROJECTIONS to 2020 
 
Predicting the future 
Several changes are expected to happen to the UK population in the next decade, 
particularly substantial ageing. This by itself will increase the burden of 
cardiovascular disease, since CVD incidence and mortality is strongly and positively 
associated to age.  
 
It is tempting to simply assume that recent trends will continue in a linear fashion to 
2020. But that would be foolish, when we consider major factors likely to push those 
trends in different directions, especially population aging, plateauing of cholesterol, 
smoking and blood pressure levels and recent large increases in obesity and 
diabetes.   
 
Potentially dramatic improvements in future therapies and more effective prevention 
strategies raise further uncertainties.  We have therefore used a cautious approach, 
as described below. 
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In tables 2 and 3 we have simply assumed that the mortality rates in 2004 would 
continue unchanged, thus reflecting only the changes in the demography. (To 
estimate the number of deaths expected in the population in 2020, we therefore 
simply applied these rates to the older population expected in 2020). 
 
PROJECTIONS FOR CHD DEATHS IN 2020 (table 2) 
This approach predicts increases for the CHD number of deaths (table 2). The 
estimate for 2020 (using the 2004 rates applied to the 2020 population), would give 
about 36,500 extra deaths, of which about 7,300 would be premature, aged below 
75. This is a conservative estimate, assuming no further decline in age-specific CHD 
death rates. The true increase is thus likely to be slightly smaller. 
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Table 2: CHD mortality 2020 projections 
MEN 
       
  
Population  
in 2020 
2004 
Mortality 
rate per 
105 
Number of 
deaths in 
2020 
Number of deaths 
in 2004 
Excess 
deaths 
Relative 
increase 
35-44 3,784,099 0.000 668 714 -46 0.94 
45-54 3,844,580 0.001 3031 2630 401 1.15 
55-64 3,504,272 0.002 7,400 6359 1041 1.16 
65-74 2,783,416 0.006 16,199 12276 3923 1.32 
75-84 1,724,155 0.016 26,767 19418 7349 1.38 
85+ 658,832 0.034 22,095 9823 12272 2.25 
   
total 
men 
76,160 51220 24940 
1.49 
WOMEN 
       
  
Population 
in 2020 
2004 
Mortality 
rate 
per 105 
Number of 
deaths in 
2020 
Number of deaths 
in 2004 
Excess 
deaths 
Relative 
increase 
35-44 3,777,686 0.000 148 160 -12 0.92 
45-54 3,911,878 0.000 588 511 77 1.15 
55-64 3,651,668 0.001 1982 1687 295 1.17 
65-74 3,030,273 0.002 7290 5633 1657 1.29 
75-84 2,047,462 0.009 17674 15677 1997 1.13 
85+ 1,016,001 0.025 25053 17493 7560 1.43 
  total women 52735 41160 11575 1.28 
  
     
MEN & WOMEN TOTAL 
 
128,895 
 
92,380 
 
36,515 
 
1.39 
 
Data sources:  ONS mortality data ; ONS population projections 
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PROJECTIONS FOR STROKE DEATHS IN 2020 (table 3) 
 
This approach predicts increases for the number of stroke deaths (table 3). The 
estimate for 2020 (using the 2004 rates applied to the 2020 population), would give 
about 22,000 extra deaths, of which about 2,400 would be premature, aged below 
75.  This is a conservative estimate, assuming no further decline in age-specific 
stroke death rates. The true increase is thus likely to be smaller. 
 
Table 3: STROKE mortality 2020 projections (conservative method, using 2004 
rates) 
 
 MEN 
Population 
in 2020 
2004 rate 
per 105 
Number of 
deaths in 
2020 
Number of 
deaths in 2004 
Excess 
deaths % Increase 
35-44 3784099 5.847 221 236 -15 0.94 
45-54 3844580 16.581 637 553 84 1.15 
55-64 3504272 40.347 1414 1215 199 1.16 
65-74 2783416 163.191 4542 3427 1115 1.33 
75-84 1724155 686.904 11843 8576 3267 1.38 
85+ 658832 2080.590 13708 6067 7641 2.26 
   total men 32366 20074 12292 1.61 
 
       
 WOMEN 
Population 
in 2020 
2004 rate 
per 105 
Number of 
deaths in 
2020 
Number of 
deaths in 2004 
Excess 
deaths % Increase 
35-44 3777686 4.369 165 179 -14 0.92 
45-54 3911878 13.451 526 457 69 1.15 
55-64 3651668 29.891 1092 929 163 1.17 
65-74 3030273 120.133 3640 2817 823 1.29 
75-84 2047462 632.832 12957 11484 1473 1.13 
85+ 1016001 2362.727 24005 16773 7232 1.43 
   total  42385 32639 9746 1.30 
  
     
MEN & WOMEN total  74,750 52,445 22,040 1.42 
 
Data source: ONS mortality data,  ONS population projections 
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PROJECTIONS FOR CHD AND STROKE DEATHS: SOME ISSUES 
These findings are in line with the projections made using the Global Burden of 
Disease (GBD) Study methodology, forecasting that CVD will remain as the leading 
cause of death and disability in high-income countries (WHO 2006).  However, GBD 
estimates do not predict a significant increase in absolute burden, and even in terms 
of disability adjusted life years (DALYs), some modelling scenarios suggest a 
decrease. However, these estimates may reflect modelling trends based simply on 
changes in smoking and diabetes only, not taking into account the other major risk 
factors. In addition, the GBD methodology has been criticized, especially due to its 
reliance on estimates for basic model inputs (Cohen 2000). These projections could 
however be used as a benchmark for any forecasting modelling exercise in the UK.  
 
Our calculations are crude and although they mainly reflect the predicted 
demographic changes, the assumptions made of the future behaviour of trends are 
very simple and may not deal adequately with strong underlying phenomena which 
are probably happening today and which could have impact in the future. Apart from 
the expected demographic changes, the increase in the burden of disease could be 
compounded by decelerations or even reversals of the mortality trends, as the 
recently reported flattening of the decreasing trend in CHD mortality in the UK 
(O’Flaherty et al., 2008, Allender et al, 2008) the US (Ford 2007) and Australia 
(Wilson 1995).  Similar trends for stroke are now being sought. 
 
If the flattening in the younger age groups represents a cohort effect, then as this 
cohort ages they will experience higher mortality, increasing the burden and 
exceeding the conservative estimates.   
 
Better forecasting of future mortality might in future benefit from the use of Bayesian 
age-period –cohort effect methods traditionally used in cancer epidemiology, and just 
recently for forecasting CVD mortality in Finland, (Huovinen 2006) as described 
below. 
 
Implications of population ageing  
Globally, CVD will remain the dominant cause of death and disability in the next few 
decades. In Finland as in the UK and in many other industrialised countries, age-
adjusted CHD mortality rates have halved recently, mainly as a result of reductions in 
major risk factors (cholesterol, smoking and blood pressure), plus additional gains 
from medical treatments (Laatikainen et al. 2005). The pressing question is: given 
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demographic ageing, what is going to happen to disease prevalence and hence the 
population burden of disease?   
 
We are witnessing an important paradox in the UK and in the majority of 
industrialised countries (and subsequently in developing countries).  Cardiovascular 
and CHD mortality rates have halved over recent decades.  The substantial 
reduction in tragic premature deaths is a great public health achievement.  But 
because of population ageing, the total numbers of deaths have not declined 
correspondingly and are likely to increase substantially. The future continuing burden 
of cardiovascular disease will increasingly affect older groups and will stretch 
healthcare systems, even in the wealthiest countries. (O’Flaherty 2007).   
  
In Finland, Huovinen and colleagues (2007) used Bayesian statistics to predict 
demographic ageing and CHD deaths up to the year 2030.    
 
The analysis used data from three areas in Finland previously defined through high 
quality Fin-risk surveys.  This produced a total population of approximately 400,000 
aged 30-99 years.  Although the number of fatal CHD events annually was fairly 
small (about 4,000), reasonably narrow confidence intervals were achieved.  The 
probability of death was based on a Bayesian age-period-cohort model. 
 
Although the Finnish population does not change in size, demographic ageing will be 
substantial, as in the UK. By 2030 the proportion above 80 years will increase from 
5.1% to 9.6% in men and from 10.5% to 14.7% in women (attributed to the 
maturation of the ‘baby boom’). They considered two alternative scenarios, firstly 
assuming that CHD mortality rates will simply continue at present levels (unlikely).  
Alternatively, if the recent decline in age-specific death rates between 1970 and 2002 
continues, deaths would continue to plummet in the young and middle-aged groups 
and CHD deaths would predominantly occur above the age of 80 years.  In both 
scenarios, the total number of CHD deaths would increase substantially, by 
approximately 70% in men and by 50-100% in women.  Over 80% of female CHD 
deaths already occur beyond the age of 80, (compared with only 40% in men, but 
rising to 76% under the more optimistic scenario in 2030).  This would represent a 
four-fold increase in deaths in the eldest men (aged 80 plus), and three-fold in the 
eldest women. This would indicate corresponding increases in incidence and, 
crucially, in prevalence. These Finnish analyses therefore have potentially major 
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implications for future health service demands in the UK and comparable countries 
(Capewell 2007). 
 
a) Improvements in future prevention and treatment? 
Huovinen and colleagues (2007) anticipate revolutionary improvements in future 
prevention and treatment.  However, expecting major gains from future treatments 
may also be optimistic.  Even if wealthy countries can afford novel and efficacious 
CHD treatments in future, the potential benefits will always be limited by four factors.  
Firstly, up to half of all cardiac deaths are sudden and therefore inaccessible to most 
healthcare interventions (Capewell et al 2001).  Secondly, having experienced the 
first cardiovascular event, even on optimal therapy, life-expectancy is still less than 
half that of a healthy individual, (Capewell et al 2001). Thirdly, even the best 
healthcare systems in the world have difficulty delivering appropriate therapies for 
more than 80% of eligible patients. Fourthly, patients often cease to take long-term 
therapies, for a range of rational and less rational reasons (Capewell 2008). 
 
In the UK, we recently calculated that maximising medications for eligible CHD 
patients could reduce deaths by approximately 20,000 annually (Unal et al 2005).  
Conversely, modest further reductions in risk factors might reduce CHD deaths by 
50,000 per year, halving current UK CHD mortality. Most evidence clearly favours 
Rose’s population approach to prevention, rather than the high risk approach, even 
though some debate continues. (Capewell 2008)  Prevention and treatment for high 
risk in individuals is also resource-intensive. Conversely, policy change at the 
national and international level can have a high impact, being effective and cost-
effective (Capewell 2008). Simple diet policy initiatives in countries as far apart as 
Finland and Mauritius have achieved substantial reductions in population cholesterol 
levels and corresponding falls in cardiovascular deaths (Laatikainen 2005, Dhowse 
1995).  Furthermore, smoke-free legislation is likely to achieve substantial economic 
gains, not just health benefits (Capewell 2008).   
 
Trend analysis of mortality rates take into account past changes but not the future 
impact of current activities. Therefore, any forecast of disease burden needs to take 
into account the potential effect of current policy decisions on future burden. As 
previously shown by MONICA (and various modelling exercises (Unal et al 2004, 
Hunink et al 1997), between 50-70% of the decline in CHD deaths observed in the 
last decades of the 20th century could be explained by changes in the incidence 
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(which in essence means changes in risk factors), and between 30-50% by a 
decrease in case fatality (attributable to treatment of patients).   
 
In conclusion, the GBD future projections take into account the possible trajectory of 
some of the risk factors.  However, a more comprehensive list of risk factors needs to 
be considered. Incorporating and quantifying the effects of both established and 
novel treatments will necessitate more versatile methodologies involving cohort 
simulations that incorporate changes in risk factors, level of treatments and 
demographics. This will require a more sophisticated modelling methodology.
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4.    THE CHALLENGE OF PREDICTING THE FUTURE CVD 
BURDEN 
 
INTRODUCTION TO CVD MODELLING 
 
CHD mortality rates have begun to fall in many developed countries, particularly in 
the last two decades (BHF Heartstats). The Bethesda Conference in 1978 posed the 
crucial but difficult question: do such CHD mortality falls in entire populations mainly 
reflect increasing use of evidence-based treatments for individual patients, or 
cardiovascular risk factor improvements across entire populations? The answer to 
this question is essential for planning effective strategies for CVD.   
 
The subsequent multi-national WHO MONICA study suggested that approximately 
one third of the CHD mortality fall in the mid 1980s/1990s was attributable to 
decreased case-fatality (mainly reflecting treatments), while some two thirds was 
attributable to fewer events (mainly reflecting prevention through reductions in major 
risk factors such as smoking, cholesterol and blood pressure) (Tunstall et al 1999).  
 
However, a more detailed understanding of CHD trends in specific populations then 
required the selection of the most powerful research design feasible. Although 
randomised trials of entire countries were obviously not realistic, modelling studies 
were.   
 
A model is “an analytical methodology that accounts for events over time and 
across populations, based on data drawn from primary or secondary sources, 
whose purpose is to estimate the effects of an intervention on valued health 
consequences and costs” (Unal et al 2004)   
 
Models can thus potentially be used to help explain past trends, or predict future 
disease burdens.  
 
Successive CHD models have become increasingly robust and sophisticated   
CHD mortality has halved in the past two decades and much of this reduction 
(around 50%-60%) is attributable to risk factor reductions (in the USA between 1968 
and 1976; in New Zealand 1974-1981, and in Scotland 1975-1994).  Since then, 
however, many effective therapies have been introduced and widely used (Ford et al 
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2007).  Thus, more recently, Goldman’s updated CHD Policy Model suggested that in 
the USA between 1980 and 1990, barely 55% of the CHD mortality decline was 
explained by risk factor reductions (Hunink et al 1997). Lopez and colleagues 
subsequently developed the Global Burden of Disease model, which has been 
valuable for international comparisons, emphasising the powerful contributions from 
elevated cholesterol, smoking and hypertension. However, neither model 
comprehensively considered specific medical therapies, nor quantified the big 
uncertainties around the model estimates.    
 
In the UK, the PREVENT model and its discrete event simulation model successor in 
the London School of Hygiene and Tropical Medicine (LSHTM) were then used to 
consider risk factors (Naidoo et al 1997). Simultaneously, a Markov model in 
Southampton  addressed heart attack and angina (Cooper et al 2002).  Although this 
project aimed to combine the two models, this proved difficult, with problems around 
reliable integration, consistency, long running times and validation.  
 
More recently, therefore, more comprehensive and validated models such as 
IMPACT have been developed (Unal et al 2004). These models aim to include all 
patient groups, all standard treatments and all major risk factors.  Conceptually 
simple, but methodologically sophisticated, all assumptions in this cell-based model 
are explicit, transparent, and subjected to rigorous sensitivity analyses (Unal et al 
2004).  In brief, the first IMPACT Model systematically synthesised information on the 
numbers of patients with different forms of CHD, the uptake of specific medical and 
surgical treatments, plus trends in the major cardiovascular risk factors, all stratified 
by age and sex.  The effectiveness of the specific therapies and risk factor changes 
was then precisely quantified using data from large cohort studies and recent meta-
analyses (Unal et al 2004, Ford et al 2007).       
 
 
SYSTEMATIC REVIEWS OF AVAILABLE MODELS 
 
Background 
Estimating the burden of disease is a complex task which could involve quantification 
of the current state but may also provide a sensible forecast of the potential future 
burden. Estimates of the future burden are by their nature provisional, since the 
assumption of that every component in the current state remains unchanged is too 
simplistic. Demographic changes may increase the burden while the greater use of 
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established and novel interventions may decrease disease incidence, mortality and 
morbidity. Many factors may therefore influence the future disease burden in a given 
population. Many of these are related to current policy decisions.   
 
The Global Burden of Disease Study (Murray and Lopez 1997, a,b,c) provided a 
useful estimate of the relative contribution of specific diseases to the overall disease 
burden. However, defining disease burden just on the basis of mortality and disability 
measures does not allow one to fully understand or explore the real, 
multidimensional burden of disease in a population. A more informative approach 
should consider not only measures of disease frequency but also the effect of health 
interventions at the population and individual level.  A simple, broad-brush approach 
is also limited because it does not allow policy makers to explore the effects of 
different disease control strategies on the burden of disease.   
 
Several policy models have therefore been developed, aiming to represent the CVD 
problem in a more comprehensive way. These approaches concentrate on modelling 
disease epidemiology and are thus able to provide estimates of the burden of 
disease in entire populations, and in certain cases, future forecasts. These 
approaches thus might potentially provide a platform to assess the contribution of 
different intervention strategies.  
 
Aim 
Our aim was to systematically review the literature on the use of models in 
cardiovascular diseases to explore policy issues at the police level, including the 
estimation of the future burden of disease. This review updates a previous systematic 
review on CHD policy models (Unal et al 2006) and expands to include models for 
stroke, peripheral arterial diseases and atrial fibrillation.  
 
Methods 
We defined a CHD policy model as any mathematical decision support tool that may 
help at a population level to explain or predict the outcome of CHD interventions 
(specific treatments or cardiovascular risk factor changes or the implementation of 
new strategies).  
 
Search strategy 
A search strategy was developed, piloted and run in MEDLINE and EMBASE 
electronic databases for the period 1966-2008. We searched for coronary heart 
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diseases and synonyms, stroke and synonyms, peripheral arterial diseases 
(including abdominal aortic aneurisms) and atrial fibrillation, with model and its 
synonyms as keywords and MeSH headings. Details of the search strategy are 
available.  As a validation of the search strategy, we were able to identify in the 
results six CHD policy models and three leading stroke models previously known to 
us. The search in electronic databases was complemented by manual review of 
included articles.   
  
Inclusion and exclusion criteria 
Papers were included if: a) their main focus was CHD, Stroke, Atrial fibrillation, or 
Peripheral artery disease (limb ischemia, intermittent claudication or aortic aneurism, 
abdominal); 
b) a modelling approach was used and; 
c) analysis was at the population level (conurbation, county, region, country or 
continent). 
 
Papers were excluded if they dealt with “single decisions” or decision making for 
individual patients.  Figure 1 illustrates the flowchart for the search and review 
process. Diabetes models were not included but have been the subject of a recent 
review by the Mt Hood collaboration (Mt Hood Modelling Group 2007.) 
 
Two reviewers (MOF and JC) independently applied the inclusion and exclusion 
criteria to the list of studies identified. Their agreement on inclusion was high and 
minor disagreements were resolved by discussion.  
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Figure 1 Flowchart of search strategy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data extraction and assessment of model quality 
Articles were categorised according to the disease area that they described. Each 
paper was then critically appraised and data was extracted by two independent 
reviewers (MOF and JC) using explicit quality criteria. There are no universally 
accepted lists of appropriate quality criteria for modelling papers.  Unal et al (Unal 
2006) proposed several criteria based on reviews by Weinstein et al (Weinstein 
2001), Edwards et al (Edwards 2000), and recent guidelines from the International 
Society for Pharmacoeconomics and Outcomes Research (Weinstein et al 2003). 
Using these sources, we assessed the models’ quality based on their sensitivity, 
validity and transparency. Papers were evaluated on the basis of whether: a 
sensitivity analysis was carried out; the validity was checked; data quality was 
Search hits:     Medline 12448, EMBASE 230,   Manual: 34 
 
Screening by title and abstract 
keywords 
CHD  
papers 
246 
 
Stroke 
papers 
67 
 
PAD 
Papers 
14 
 
AF 
papers 
3 
Inclusion/Exclusion Criteria 
CHD models 
papers 
Stroke models 
papers 
PAD models 
papers 
AF  models 
papers 
INCLUDED: 
105 
 
Excluded: 
Single decision: 
117 
INCLUDED: 
14 
 
Excluded: 
Single decision: 
49 
 
INCLUDED: 
12 
 
Excluded: 
1: Review 
2: Not modelling 
 
INCLUDED: 
3 
 
Excluded: 
0 
 
KEY:   CHD: Coronary heart disease. PAD: Peripheral artery disease AF: Atrial fibrillation 
Note: all the PAD papers are models evaluating screening and management strategies for abdominal aortic aneurisms.  All the AF 
papers are papers evaluating rhythm and antithrombotic strategies in AF. Since the policy and burden problem of these diseases is 
simple, we forego the application of the single issue exclusion criteria for these models.  
 56 
reported; illustrative examples were provided; assumptions stated; if the model was 
potentially available to the reader (transparency); and, if potential limitations were 
specified or discussed, (such as assumptions, confounding, lag times and competing 
causes). The model evaluation was based on authors' reporting on that specific item 
in the related articles.  
 
Results 
From 12,712 initial papers, we obtained a total of 134 articles describing 70 different 
models which were finally included:  46 CHD models, 9 stroke models, 12 PAD (all 
dealing with abdominal aortic aneurisms) and 3 AF models (Figure 1).  166 papers 
were excluded being models with the purpose of exploring a single decision; 1 was a 
systematic review of aneurism models and 1 was not a modelling paper.  
 
The PAD and AF models were not true population models. Using cohort simulation 
restricted to an age group and male gender, they explore policy issues for abdominal 
aortic aneurism (screening and early surgery) and for atrial fibrillation (antithrombotic 
therapy and rhythm control).  
 
Model logic used 
The modelling methods most commonly used were discrete event simulation (14 
models), Multi-state life tables (12 models), Markov models (10), cell-based or 
spreadsheet (8 models), “cost offset” model (1) and Population Impact Measure 
model (1).  It was not possible to catalogue 4 models because the model logic was 
not adequately described.   
  
Transparency and limitations of the models 
Two thirds of the models (46/70, 65%) explicitly stated their key assumptions. 
Working versions of the models were potentially available in just four, all describing 
CHD. About one third of the models reported on limitations of their methodology such 
as competing causes (8), lag times (7), ignoring confounding (8) or underlying trends 
(1), ignoring class/ethnicity (1), or generalisability (1) . 
 
Sensitivity analysis 
Because all models rely on imperfect data and assumptions to derive estimates, 
sensitivity analysis is desirable to evaluate the degree of uncertainty in the outputs. 
This could be achieved by modifying the parameter’s value by an arbitrary amount 
(deterministic sensitivity analysis) or by allowing the parameter to vary stochastically, 
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usually through a Montecarlo simulation (probabilistic sensitivity analysis).  Sensitivity 
analyses were reported in 33 models (47%), most of them (28) being deterministic, 
not probabilistic. Most models conducted sensitivity analysis by varying one 
parameter at a time (22) while only six conducted the more rigorous multi-way 
analyses (varying various parameters simultaneously). Truly probabilistic sensitivity 
analyses were reported by only five models.   
 
Model Validation 
Validity - how well the model portrays the real world - can be assessed in various 
ways, including face validity, content validity, comparative validity, replicative validity 
and predictive validity. 
 
Validation of CHD models  
Assessment of validity was reported in very few models. In the CHD Health Policy 
Model, validation was done by comparing the CHD deaths estimated by the model 
with the actual CHD deaths observed in 1990 (Hunink et al 1997). The IMPACT 
Model also compared the estimated fall in CHD deaths with the observed fall in 
deaths in specific age and sex categories (Capewell et al 1999, Unal et al 2004). The 
PREVENT model compared model estimates with another estimation method 
(Bronnum-Hansen et al 2000). The Cardiovascular Life Expectancy Model examined 
predictive validity by comparing the model estimates with events observed in primary 
and secondary prevention trials (Grover 1998, Grover 1999). The original 1992 
Cardiovascular Life Expectancy model was similarly validated against the data set 
from the Lipid Research Clinic cohort (Hamilton et al 1995). The Whitfield (Barnsley) 
model was validated by comparing estimated hospital admissions against observed 
admissions (Whitfield et al 2006). 
 
The CHD Health Policy model was calibrated using life years estimated from the 
model compared with life expectancy from 1980 national statistics (Tsevat et al 
1991). Only two of the models had been replicated in different populations; 
PREVENT (Naidoo 1997, Naidoo 1998) and IMPACT (Capewell 1999,Capewell 
2000,Critchley 2003a Critchley 2003b-Critchley 2004, Bennet 2006, Ford et al 2007). 
 
Stroke models were more comprehensively validated. MORUCOS (Mihaloupolos 
et al. 2005) assessed face validity via peer review by a professional body.  They 
compared their estimate of stroke incidence with those of the NEMESIS stroke 
incidence study, and compared results of a previous version of the model with the 
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latest one. The Duke Stroke Prevention Policy Model (Matchar 1997), Nijhuis (2006) 
and Schau (2003) all compared their incidence estimates with those observed in the 
high quality cohort studies and Tobias (2007) with successive rounds of a stroke 
registry. No stroke model had been replicated in other populations.  
One PAD model (Wanhainen 2005) compared their results with those observed in 
two clinical trials.  
 
Model outcomes 
The most common type of outcome reported were life expectancy-based measures 
(e.g. life expectancy, life years gained, life years lost, disability adjusted life years or 
quality adjusted life years), which were provided by 35 models. Cost estimates were 
presented in 27 models, although fewer models were able to produce more detailed 
resource-used-related outcomes (6 models). Mortality-based measures like number 
of deaths, deaths prevented; survival or mortality rates were produced by 24 models. 
Prevalence and incidence estimates were available in 24 models. Prevented events 
were available in 10 models, while only one model reported population impact 
numbers.  
 
Predicting trends and Burden 
Except for the Global Burden of Disease Study, the models discussed in this review 
were not primarily designed to estimate or forecast disease burden. However, since 
many of them produce mortality-based outcome measures, they can provide some 
estimates of disease burden for a given population.   
 
Several CHD models have the capability of predicting trends for their reported 
outcomes, which are typically a mortality-based measure. These are: the CHD Policy 
Model, PREVENT, IMPACT, Global Burden of Disease, CHD Policy Analysis and 
Whitfield 2006. Among stroke models, Schau (2003) and Nijhuis (2006) can forecast 
stroke incidence and mortality. The PAD and AF models are basically decision 
models, and their use for burden of disease estimation purposes is severely limited. 
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MAIN CHD MODELS 
 
We identified seven notable models. Each is briefly summarised below.    
 
Coronary Heart Disease Policy Model (CHDP, USA) 
The CHDP is a state-transition, cell-based model developed in the 1980s (Weinstein 
1987). It was initially used to examine trends in CHD mortality (Hunink 1997, 
Goldman 2001) and expected gains in life expectancy from risk factor modifications 
(Tsevat 1991). This model was also used to evaluate the cost-effectiveness of 
specific medical interventions for primary and secondary prevention of CHD (Gaspoz 
2002, Goldman 1991, Phillips 2000, Prosser 2000) and health promotion activities 
(Tosteson 1997). 
 
The original CHDP model was based on the 1980 US population and mortality 
statistics. It consists of three sub-models: 
- A demographical / epidemiological model, which represents the disease-free 
population aged 35–84 years, stratified by sex, age group and cardiovascular risk 
factors. This model includes risk factors as categorical variables resulting in more 
than 5,000 cells in total. It then uses a logistic risk function based on the Framingham 
equation to estimate the annual incidence rates of CHD events for each cohort. 
- A bridge model, which covers subjects for the first 30 days after they develop CHD. 
Using CHD incidence data from Minnesota, the model initially determines whether 
the first event is angina, myocardial infarction or cardiac arrest.  
- A disease history model, which includes the survivors after the first 30 days, 
places them in 12 CHD states by age and sex, and then follows them through 
treatment pathways. 
 
This model allows the user to simulate the effects of an intervention (either risk factor 
modification, or therapy) by changing case fatality rates and observing the effect on 
mortality, morbidity and costs for up to 30 years. 
 
CHD Policy Analysis Model (UK) 
This comprised two distinct parts. The primary prevention component of the model 
developed by the London School of Hygiene and Tropical Medicine aimed to 
simulate the impact of different primary prevention strategies on benefits and costs 
(Babad 2002). The treatment component of the model was developed in the 
Universities of Southampton and Birmingham (Cooper 2002) to evaluate the impact 
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of different treatments given to two different groups of CHD patients, stable angina or 
acute myocardial infarction.  
 
PREVENT (Netherlands & UK) 
This was a cell-based model developed in the Netherlands during the 1980s 
(Gunning-Schepers et al 1989). It has been used to estimate the health benefits of 
changes in population risk factor prevalence by comparing;  i) continuation of existing 
trends with  ii) alteration of the proportions of the population with given risk factor 
levels. The model allowed one risk factor to be associated with more than one 
disease and one disease to be associated with more than one risk factor. 
Demographic evolution was also taken into account in simulations. 
 
Cardiovascular Life Expectancy Model (Canada) 
This was initially developed by Grover in 1992 in Canada to examine the cost-
effectiveness of different treatment options for CHD (Grover et al 1992). From 1998 
onwards, the model was also described as a Markov model. The model includes 
primary and secondary prevention parts. The primary CHD part calculates the annual 
probability of dying (from CHD or other causes) and the annual risk of CHD events 
(with or without intervention) for a person without symptomatic CHD at entry to the 
model. The annual risk of developing specific CHD endpoints is based on data from 
the Framingham Heart Study. After developing CHD, a person then moves to the 
secondary CHD model. This part calculates the risk of dying during the 12 months 
following a non-fatal myocardial infarction. The risk estimations are based on the 
Framingham logistic equations for primary events after adjustment for the presence 
of CHD. The difference between the predicted annual cumulative mortality with and 
without the intervention over the remaining total life expectancy then represents the 
total years of life saved after that intervention. 
 
IMPACT CHD mortality model (USA, England and Wales, Scotland, Ireland, 
Italy, Finland, Sweden, Iceland, New Zealand, and China) 
IMPACT is a cell-based model originally developed by Capewell and colleagues in 
the 1990s (Capewell et al, 1999). Using a MS EXCEL spreadsheet, this model 
combines data selected from the best sources on patient numbers, treatment uptake, 
treatment effectiveness, and risk factor trends. The consequent mortality effects 
reflect large cohort studies and meta-analyses. The deaths prevented or 
postponed (DPPs) over a specified time period are then estimated. The model can 
be used to estimate the proportion of change in mortality over a specific time period 
 61  
attributable to specific treatments or risk factor changes. It can also estimate the 
future consequences of altering treatment strategies or changing population risk. The 
model also estimates life years gained and cost-effectiveness for specific 
interventions. 
 
WHO Global Burden of Disease model (GBD) 
This model, developed at WHO by Lopez and Murray, derives estimates based on 
population attributable risk (PAR %). The model estimates the attributable burden of 
disease for a specific risk factor, population and time, against a theoretical total 
population defined in the low risk category for that risk. (Murray 1997a, Murray 
1997b). The GBD Model has five components: causes of death, descriptive 
epidemiology of disabling sequelae, burden attributed to selected risk factors, 
projections of burden for the future and sensitivity analyses. Cause of death data 
come from vital registrations or other sources. Data on 107 disorders and selected 
disabling sequel were investigated regarding average age of onset, duration, 
incidence and prevalence. Burden of disease and injury attributable to ten major risk 
factors were then calculated. The model uses attributable fractions, taken from 
reviews and meta-analyses, applied to the population of a region to calculate the 
burden of disease attributable to these risk factors (Murray 1997a). Where data were 
not available, assumed values were used based on comparative regions. Among 
other outcome measures, the main burden of disease measure used is the disability 
adjusted life year (DALY), calculated as the sum of years lost and years lived with 
disability (Murray 1997b). 
 
A similar methodology was applied in several other countries.  Examples include 
Australia’s Burden of Disease study in 1999 (Mathers 1999); Victoria’s Burden of 
Disease Study in 2001 (Victoria Department of Human Services 2001), South Africa’s 
Burden of Disease Study in 2000, Holland’s Burden of Disease study in 2000 (Melse 
2000).  
 
Whitfield 2006 (Barnsley, UK) 
This model (Whitfield, Gillet & Holmes, 2006) was designed to explore the impact of 
a population level risk reduction on future hospitalization for CVD and chronic renal 
disease, and costs to estimate the potential impact of investing in public health 
interventions. The model used a “cost offset” approach, estimating the risk level of 
the target population (in this case five primary care trust populations in South 
Yorkshire) using the Framingham equation, and for the diabetes subpopulation, the 
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UKPDS risk engine. The model also incorporates the inter-relationship between 
chronic kidney diseases and risk of CVD. Interventions are modelled as the expected 
population effect estimated by literature review and a panel of experts.    
 
MAIN STROKE MODELS 
 
We identified nine stroke models. (This includes the Whitfield model which was 
described in the preceding section and will not be described again here).  
 
Schau 2003 (Denmark) 
This model estimates annual stroke incidence in any defined population based on 
demographic factors and using information from several cohorts (Schau 2003). 
Baseline incidence is then modified by the specific distribution of risk factors within 
the population of interest. For those populations with missing data on risk factor 
distribution, default values can be used.  The model considers hypertension, atrial 
fibrillation, diabetes, smoking, ischemic heart disease, previous history of stroke or 
transient ischemic attack and ethnicity.  
 
Tobias 2007 (New Zealand) 
The aim of this model was to provide internally consistent estimates of registry based 
stroke incidence, prevalence and mortality; and to perform projections for these 
measures to 2011 (Tobias 2007).  It used a multistate life table approach, based on 
the ARCOS stroke registry system to estimate stroke prevalence and incidence by 
using several overlapping sources. It does not consider any risk factors or 
treatments, and its projections only take into account demographic changes and 
assume a constantly decreasing trend in stroke burden.  
 
Rotterdam Ischemic heart disease and Stroke Computer Simulation Model 
(RISC, Netherlands) 
The RISC Model (Nijhuis 2006) is a Markov multistate model with the aim of 
evaluating the effect of cardiovascular risk factors on life expectancy and disease 
free life expectancy, based on data from the Rotterdam Study. It models ischemic 
heart disease, ischemic stroke, ischemic heart disease and stroke, cardiovascular 
death and non cardiovascular death. Risk factors included in the model are atrial 
fibrillation, previous stroke, smoking, blood cholesterol and HDL-C, systolic and 
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diastolic blood pressure, hypertension, diabetes, body mass index, family history of 
CVD and the ankle-brachial index.  Treatment effects are not modelled.     
 
Sundberg 2003 (Sweden) 
This model (Sundeberg 2003) has four modules:  
 1)  “Rates module”, that provides  mortality rates for stroke, ischemic heart disease 
and other causes;   
2) “Standard module” that estimates the incidence of new strokes and expected 
outcomes of strokes, and applied to a synthetic cohort of stroke patients;   
3) “Weighting module” that applies the standard module estimates to a defined 
population and   
4) “Survival model” that models survival after a stroke events.  
 
The outputs of the weighting module are combined with other parameters to 
represent patients flow in predefined care pathways that allows the estimation of 
resource use. The risk factors considered are: atrial fibrillation, heart failure, carotid 
disease, smoking, hypertension and diabetes. The patient groups considered are 
transient ischemic attacks, ischemic strokes, and hemorrhagic strokes. The available 
interventions are stroke units, strategies involving diagnostic procedures, surgery for 
hemorrhagic strokes, thrombolysis, neuroprotective agents and rehabilitation.  
 
Duke Stroke Policy and Prevention Model (SPPM) (USA) 
The SPPM (Matchar et al 1997) provides a modelling platform for assessing a range 
of policy interventions in primary prevention and treatments. It follows simulated 
patients, with a history of previous cerebrovascular disease and those who are 
asymptomatic as they develop a transient ischemic attack, myocardial infarction, 
ischemic stroke, hemorrhagic stroke, bleeding, other treatment complications and 
death.  The model simultaneously computes dependent flows of costs and quality 
adjusted life years so that each simulated patient generates an estimate of survival 
time, a quality-adjusted survival time and costs. It has a natural history module (the 
cohort simulation itself, using a Markov multistate approach); an interventions module 
and utilities module, and a cost module. It has been used in a secondary prevention 
scenario (Matchar et al 2005) and to analyse the treatment of acute stroke (Samsa et 
al 1999).  
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Model of Resource Utilization, Costs and Outcomes for Stroke (MORUCOS) 
(Australia) 
This model (Mihaloupoulos et al 2005) was originally commissioned by the National 
Stroke Foundation in Australia to aid its advocacy role for government policy. The 
model provides a comprehensive description of the incidence and prevalence of 
stroke in specified populations. It quantifies the associated resource use and costs; 
the capacity to predict disease burden and associated health services requirements 
through time; and, the ability to evaluate stroke interventions from primary prevention 
through palliation. The model has two versions, one that specifies treatment 
pathways and the other that considers stroke subtypes.  
 
MORUCOS has four modules:   
a) a natural history module (that estimates incidence and events rates, and defined 
clinical pathways);   
b) a cost module (that estimates resource use, production gain or losses from a 
societal perspective);   
c) an outcomes module (that estimates disability adjusted life years as the main 
outcome of the model) and finally,  
 d) an interventions module (that allows modifications of the base case through 
changes in parameters in the natural history module). 
 
 It does not contemplate any risk factors. It has been used to estimate costs after 
stroke (Dewey 2004, Dewey 2001; Dewey 2003) and the evaluation of two 
interventions (Moodie et al 2004). 
 
Struijs 2005 (Netherlands) 
The purpose of this model (Struijs et al 2005) is to estimate the effects of 
demographic aging together with changes in trends in major risk factors for stroke 
(hypertension and smoking) in the Dutch population. The model calculates the 
annual number of new stroke cases, using incidence estimated by age, sex, 
hypertension and smoking status. Using a dynamic multi-state life table approach 
integrates incidence rates, prevalence rates, case fatality rates, relative risks and 
transition probabilities from smoking and hypertension, the model provides an 
estimate in 2020 for incidence, prevalence and potential years of life lost. It presents 
the results under 5 scenarios: a baseline scenario for 2000, a change in the 
population demographics, a change in hypertension trends, a change in smoking 
trends and the combined changes in hypertension and smoking simultaneously.  
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Stroke Treatment Economic Model (STEM)  (USA) 
The STEM model (Caro et al 1999) allows the identification of costs drivers of stroke 
in both the short and long term. The aim is to estimate the long term economic 
impact of the treatment of acute stroke, and compare the impact in different 
subpopulations. STEM has a short term module, (that estimates the number of 
survivors and its functional state); a long term module, (a Markov multistate model 
that model the movement of patients between hospital, rehabilitation centre, nursing 
home, retiring home, home and death); and a bridge module, (that groups survivors 
from the acute module according characteristics that drives the projections, patient 
disability and place of residence). It produces as outcomes total costs and their 
accumulation over time and patient survival  (Caro et al 1999).   
 
Main Peripheral Arterial Disease (PAD) and Atrial Fibrillation (AF) models 
The only models we identified dealing with peripheral arterial diseases were papers 
exploring policy issues around the decision to perform screening for aortic abdominal 
aneurisms. These were mainly economic evaluations of the problem using head to 
head comparisons of different strategies and timing of screening interventions. They 
mostly simulated close cohorts of men with a narrow age range, so the potential to 
estimate the burden of disease is limited. The reader is referred to the excellent 
review by Campbell et al. (2007) for details of these models.   
 
Similarly, all three Atrial Fibrillation models were exercises confined to exploring the 
policy issues around antithrombotic therapies and rhythm control strategies.(Caro 
2004, Eckman 1998, Greenberg 1996). 
  
CVD Models: Key Issues 
We found 70 different policy models dealing with different diseases covering part of 
the spectrum of cardiovascular diseases. Although the models used varying 
methodologies, many of the CHD and stroke models used a cohort simulation 
approach that could be used to produce forecasts. Model quality varied considerably, 
with only 65% explicitly presenting assumptions, and very few performing adequate 
sensitivity analyses. The majority did not provide clear descriptions of their 
methodology, nor provide access to a working version of the model to permit 
judgement of its strengths and limitations. None of the models identified in this review 
could be described as comprehensive CVD models. However, some, like the 
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Whitfield model, RISC model and SPPM, allow the simple modelling of specific 
diseases or disease outcomes for both CHD and stroke.  
 
The Global Burden of Disease study was the only one identified in this review whose 
explicit objective was the estimation of burden of disease. This is in part because the 
meaning of “disease burden” can be ambiguous and could potentially include not 
only mortality and morbidity burden measures but also quality of life, and disability 
adjusted life years. If we accept a broader definition for disease burden, many of the 
models described here could be used to estimate or forecast the disease burden in a 
population. In particular, those models based on cohort simulation techniques 
(discrete event simulations, Markov, or Multi-stats life tables) could provide several 
measures of burden based on mortality, disability adjusted measures or resource 
use.   
 
We followed a systematic approach to identifying studies for the review, guided by a 
clear definition of epidemiological models with the aim of policy analysis, including 
burden of disease estimation, using a comprehensive search strategy. However, we 
cannot be completely sure that all studies have been included, particularly 
government reports using a modelling approach or those published in the grey 
literature. Our focus was on population and disease burden outcomes, so we may 
have missed some health economics modelling exercises that might be useful to 
estimate the associated economic burden. However, most of the studies explicitly 
excluded were single decision analyses which were unsuitable to provide answers at 
the population level.  
 
This study expands the findings of Unal et al (2006), though few new CHD models 
were identified. However, some of the previously known models have been recently 
used to provide some new analysis (e.g. IMPACT, US CHD Policy Model). This study 
is the first to produce a systematic review of stroke models. With the exception of 
policy issues regarding the management of aortic abdominal aneurism and atrial 
fibrillation, other important cardiovascular clinical problems have not been addressed 
using a modelling approach, particularly peripheral arterial disease.  
 
Not a single existing model could provide features that allow estimation of current 
and future burden of disease and to explore the effect of different policy scenarios.  
CVD modeling is still a developing field, searching for common methodological and 
reporting standards. In this sense, it is useful to learn from the diabetes modeling 
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community (MT Hood Modeling Group 2007), which has advanced the field by formal 
model comparisons aimed to improve methods and approaches.  
 
An important finding of our review is the absence of truly comprehensive CVD 
models. An explanation for this may be the important methodological challenges that 
exist.  Issues include trying to model a complex causality network, interrelated 
diseases, different timescales, multiple interventions and many different meaningful 
outcomes. However, since many diseases shared similar determinants, the drive 
towards increasing comprehensiveness is justified. The estimation of current and 
future burden of disease present three key challenges, a) finding ways to describe 
the multidimensional nature of the disease burden concept b) improving forecast 
methods and crucially, c) validating the different models.  
A more comprehensive validation programme therefore needs to be conducted by 
committed modellers, not only exploring issues related to model face validity as 
defined by its potential users, but also comprising internal validity and consistency 
checks, a comparison of outputs with other models to asses concurrent validity and 
calibration to the disease epidemiology in a particular population.  
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Figure 2 Publication Standards for CVD modelling papers 
 
• Aims of the project 
• Structure and methods of the model: 
o Representation of the natural history of the condition: 
 Risk factors, disease groups, outcomes 
 Time horizons 
 Comprehensiveness 
• incidence and primary prevention interventions 
• Case fatality and treatments 
o Model logic: 
 Mathematical operations to produce the outputs 
o Model Outputs: 
 Relevance 
o Model Inputs: 
• Data quality (data availability, how up to date, comprehensive, any 
gaps in certain population groups or interventions). Reasons for 
selecting or excluding specific data sources 
o Assumptions and its rationale 
o Sensitivity analyses  
 One way or multiway 
 Probabilistic or deterministic 
• Model Validation: 
o Extent of validation (face validity, concurrent validity, predictive 
validity) 
o Replication of the model in different populations 
o Transparency:  
 Detailed methodological description  
 public availability of the model 
• Strengths and Limitations 
o Model 
o Data 
o Assumptions 
 
• Social and economic policy implications of model outcomes 
• Suggestions for future research 
 
 
Model transparency is also a key issue. Transparency greatly increases its value to 
potential users and also represents an important approach to increase the knowledge 
available to the modeling and decision-making community.  The conduct, reporting 
and appraisal of modelling studies need to be standardised in order to increase the 
current unsatisfactory level of transparency.  In particular, detailed discussions of 
methodology, assumptions and limitations are needed. Various quality standards 
have been proposed in different publications, mainly within the health economics and 
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diabetes modelling communities (Philips 2006, Philips 2004a, Weinstein 2003, 
Sculpher 2000, ADA 2004, Weinstein 2001, Philips 2004b).  However, Unal et al 
recently suggested publication standards for CHD policy models (Unal et al 2006), 
which we have now extended to cover issues relevant to all CVD diseases (Figure 2). 
Despite the importance of model validity, few studies presented extensive validation 
information. Transparency, Convergent validity, Face Validity and some sort of peer 
review are thus minimum standards for a CVD model.  
 
Although standardised reporting and publication is also key requirement, the 
complexity of current models suggest that public availability of models for inspection 
and use by the modeller community may better help to overcome the necessary 
limitations imposed by the traditional journal format. 
 
Conclusions 
There is a range of existing models which can potentially provide insights for disease 
burden estimation or policy analysis for CHD or stroke. However, substantial work is 
needed to achieve truly comprehensive and valid CVD models. The field requires 
advances both in modelling methodology and also in increasing the perceived 
usefulness of decision tools.   
 
 
OTHER RELEVANT MODELLING WORK CURRENTLY TAKING PLACE 
 
In order to compile a list of ongoing projects in CVD modelling, we also conducted an 
extensive consultation with people who have been working with the main models 
identified in our search, and also with colleagues who are recognised modelling 
experts.  This list is not necessarily complete, but does attempt to highlight all the 
high quality ongoing projects that might potentially be used as examples of best 
modelling practice.  To include projects in this list, we use similar criteria to those 
used in the systematic review.  
 
Dynamo-HIA (Netherlands) 
The purpose of this project is to design a stochastic, dynamic micro simulation with 
explicit risk factor states for annual, population based data that models varying 
chronic disease processes with a discrete time frame. The main use of the model is 
to allow the user to estimate health impact assessment - the effect of policy 
interventions by modifying key parameters in the model, to make projections and to 
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show the development of the disease process over time. DYNAMO-HIA aims to 
contribute to informed policy making, both on the EU level and the national level, by 
providing an instrument that enables health experts to predict the magnitude of 
health consequences that result from changing health determinants, using generally 
available data. DYNAMO-HIA will build upon existing modelling experiences in 
individual countries to develop a generally applicable instrument for health impact 
assessment. Data required by the instrument will be that which is usually available 
for most countries. DYNAMO-HIA will be implemented in the form of a user-friendly 
software tool. The focus of this model will be cardiovascular disease and diabetes, 
and cancer. As an illustration of the method, the model will be applied to estimate the 
potential health gain of: 
 
• achieving in all EU-countries the situation of the best-performing country with 
regard to smoking, obesity and alcohol consumption  
• implementing in the EU and its member countries several realistic policy 
options, for instance:  
 Tax increases on tobacco or alcohol  
 Changing price policies for food  
 Curtailing advertising of energy-dense food to children 
When DYNAMO-HIA has been developed, it will be made publicly available via a 
website, including instructions for its use. Also the datasets on risk factors and 
diseases compiled for the example application in this project will be available from 
this website. Inclusion in a large European website on health information, as aimed 
for by the EUPHIX project, will be attempted.  
More information: http://www.dynamo-hia.eu/object_class/dyhia_aims.html   
 
Archimedes (USA) 
The Archimedes Model is a powerful tool that can be used to answer clinical and 
administrative questions in health care. It is a comprehensive, continuous, trial-
validated simulation model of human physiology and health care systems originally 
developed at Kaiser Permanente and now marketed by the independent organisation 
Archimedes Inc.  The model currently includes several cardiovascular diseases 
(coronary artery disease, congestive heart failure, stroke) as well as many others 
(diabetes, cancer, asthma) in a single integrated system, enabling it to model co-
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morbidities, syndromes, medications with multiple effects, and more. It can be used 
to explore the effects of a wide variety of health care interventions on the 
progression, logistics, and economic outcomes of major diseases in a complex health 
care system. The simulation is at the level of biological, clinical and administrative 
detail at which interventions have their effects and clinical decisions are made. 
Potential applications include the design of guidelines, analysis of best practices, 
estimation of return on investment of care management programs, setting of clinical 
targets, priority setting, strategic goals, forecasting, design of performance measures, 
and research design. 
More information: http://archimedesmodel.com/index.html 
 
CHD Policy Model (USA) 
The Coronary Heart Disease Policy (CHDP) Model is a state-transition, cell based 
model developed in the 1980s by Weinstein and Goldman. The model was initially 
based on the 1980 US population and mortality statistics. It consists of three sub-
models: A) demographical/epidemiological model, which represents the disease-free 
population aged 35–84 years, stratified by sex, age group and cardiovascular risk 
factors. This model includes risk factors as categorical variables, therefore over 
5,000 cells are required in total. It then uses a logistic risk function based on the 
Framingham equation to estimate the annual incidence rates of CHD events for each 
cohort. B) bridge model, which covers subjects for the first 30 days after they develop 
coronary disease. The model initially determines whether the first event is angina, 
myocardial infarction or cardiac arrest. C) disease history model, which includes the 
survivors after the first 30 days, places them in 12 CHD states by age and sex, and 
then follows them through treatment pathways. 
More information: http://content.onlinejacc.org/cgi/content/abstract/38/4/1012 
 
Foresight Obesity Model (UK) 
The Foresight Obesity 2 model purpose is to quantify both recent history and future 
change in obesity levels for the England and Wales population. It uses a stochastic 
cohort simulation approach with estimated probabilities of transfer from one BMI level 
to another with age. The result provides a longitudinal growth model of the UK 
population with predicted continuous BMI levels across the age range and by gender 
for each year from 2005 to 2050. The component disease data sets allow modelled 
individuals to contract, survive or die from the set of obesity-related diseases, by 
calculating predicted attributable illness and death rates consequent on these levels 
of BMI. 
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More information: http://www.foresight.gov.uk/Obesity/Obesity_final/Index.html 
 
Global Burden of Disease (WHO) 
The new Global Burden of Diseases, Injuries, and Risk Factors (GBD) study, which 
commenced in  2007, represents the first major effort at a systematic revision of 
estimates in health for every region in the world. Updating and improving on the 
paradigm established by the original 1996 study, this major revision unites a 
community of epidemiological experts and leaders in public health research from 
around the globe to assess trends in the state of all major diseases, injuries, and risk 
factors. The original project created a common metric to estimate morbidity and 
mortality for regions that collectively span the world's population, generating 
comparable information on incidence and prevalence in global health. This ambitious 
new effort will provide updated information on past, present, and forecasted levels of 
disease and injury, while raising awareness and understanding of the causal factors 
behind them. In a uniquely inclusive enterprise, the project's global community of 
participants will work together to produce new sets of estimates, powerful and easy-
to-use tools for research and teaching, and comprehensive analyses. To further 
expand engagement with the GBD, the process of the new study will be fully 
transparent, with both methods and results publicly accessible. As a whole, the study 
stands to significantly revise our comprehension of global health, while providing 
information in a way that is maximally useful for funders and policy-makers. 
More information: http://www.globalburden.org/ 
 
POHEM (Canada) 
POHEM is a continuous, time-longitudinal, Monte Carlo microsimulation model of 
health and disease using equations and sub-models developed at Statistics Canada 
as well as drawn from the medical literature. The model simulates representative 
populations and allows the rational comparison of competing health intervention 
alternatives, in a framework that captures the effects of disease interactions. POHEM 
is currently being used to build a microsimulation model of acute myocardial 
infarction (AMI) in collaboration with cardiac researchers in Canada. The purpose of 
the model is to project the burden of AMI and to compare the relative impact of 
various risk factor modifications through lifestyle and drug therapies on outcomes 
and costs. They are currently using it to inform the Canadian Heart Health Strategy, a 
large network of leading Canadian cardiac researchers that are preparing a report to 
our parliament, (not yet published).  It also has been used to project trends in cardiac 
procedures by health region in the province of British Columbia.  Also, this model 
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includes a validated incidence prediction model of diabetes (not yet published). This 
work is on-going, with plans to implement it in POHEM.  
More information: http://www.statcan.ca/english/spsd/Pohem.htm 
 
RIVM CDM (Netherlands) 
The RIVM Chronic Disease Model (CDM) is a multi-state transition model, based on 
the life table method. It has been developed as a tool to describe the morbidity and 
mortality effects of changes of and interventions on chronic disease risk factors. It is 
a comprehensive model, covering major risk factors (cholesterol, systolic blood 
pressure, smoking, physical activity level, and body mass index) and relevant CVD 
states (acute myocardial infarction, other coronary heart disease, stroke, and chronic 
heart failure). It also modelled 20 other diseases, but does not include any 
treatments. Related transition between states is possible due to changes between 
classes for any risk factor, incidence, remission and progress for the considered 
diseases, and mortality. The model describes the life course of cohorts in terms of 
changes between risk factor classes and changes between disease states over the 
simulation time period. The main model outcome variables are incidence, prevalence 
and mortality numbers specified by disease, and quality of life adjusted outcomes.   
More information http://rivm.openrepository.com/rivm/    
 
POPMOD (WHO) 
PopMod simulates the evolution in time of an arbitrary population subject to births, 
deaths and two distinct disease conditions, by age and sex. The model is 
implemented in four states which comprise two groups with specific disease 
conditions, a group with the combined condition and a group with neither of the 
conditions. The states are denominated for convenience X, C, XC and S, 
respectively. Disease state entirely determines health status and disease and 
mortality risk for its members. PopMod simulates the time evolution of the population 
by means of a system of ordinary differential equations. Basic PopMod output 
consists of the size of the population age-sex groups reported at yearly intervals. 
From this output further information is derived. Estimates of the severity of health 
states are required for full results, which include standard life-table measures as well 
as a variety of other summary measures of population health. An extended model 
has now been developed that considers not only preventive interventions, but also a 
range of treatment options.  
More information: http://www.who.int/choice/toolkit/pop_mod/en/index.html 
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PREVENT (Netherlands) 
The Prevent model is a dynamic population model that can handle multiple risk 
factors and diseases simultaneously. The first version was developed by Louise 
Gunning-Schepers and Jan Barendregt in 1989. It linked risk factor exposure to 
disease-specific mortality, and through that to total mortality. Changes in risk factor 
exposure translate (by way of potential impact fractions, or PIFs) into changes in 
excess risk with time lags. Prevent calculates two scenarios, one called ‘reference’, 
and one ‘intervention’. These scenarios differ only in a risk factor intervention the 
user can specify, consequently all the differences between the two scenarios can be 
attributed to that intervention.  
 
The model has been through a number of upgrades, and since version 2.1 Jan 
Barendregt has become the sole responsible author. An important upgrade was the 
addition of disease-specific and total morbidity (and, related to that, disability and 
health care costs), which stabilised in version 2.95. New major changes in the current 
version (3.0) are an important conceptual change is that the difference between risk 
factors and diseases has largely become semantic: risk factors can be risk factors for 
other risk factors, diseases can be risk factors for other diseases and for risk factors. 
The current version allows defining ‘causal web’ risk factor/disease relations 
(although does not encourage spaghetti-like risk factor specifications) but also simple 
relations such as letting the CVA incidence increase as a consequence of a higher 
IHD prevalence. A major extension is that risk factors can now be either categorical 
or continuous. Categorical risk factors can have as many categories as desired, each 
associated with a relative risk. Continuous risk factors can be of various distributions 
(Normal, lognormal, Weibull), and have a risk function associated with it. The risk 
function relates risk to level of exposure, and can be either linear, two-piecewise 
linear, or logit.  Population projections can now in addition to being calculated also be 
provided as input. When the option of calculated projections is chosen the reference 
and intervention population projections will differ as a consequence of different risk 
factor prevalence. When the population projection is input the two scenarios will use 
the same projection. 
 
WHO CHOICE Generalized Cost effectiveness modelling (WHO) 
The WHO CHOICE programme assembles regional databases on the costs, impact 
on population health and cost-effectiveness of key health interventions. It also 
provides a contextualization tool which makes it possible to adapt regional results to 
the country level. This work started in 1998 with the development of standard tools 
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and methods which have been used to generate the regional databases. They 
developed an extension of cost effective analyses to inform better policy decisions at 
national or regional level called “generalized cost effectiveness analysis”. Essentially 
GCEA can be summarised in two propositions:  
1) The costs and benefits of a set of related interventions should be evaluated with 
respect to the counterfactual of the null set of the related interventions. This provides 
the complete set of information for evaluating both independent and mutually 
exclusive options to identify the health maximizing combination of interventions for 
any given budget.   
2) Results of CEA should initially be presented in a single league table as the first 
step of policy analysis. Subsequently the decision would be made about the 
appropriate cut point for classifying interventions as very cost-effective, very cost 
ineffective and somewhere in.  
More information: http://www.who.int/choice/en/  
 
Organization for Economic Co-operation and Development Modelling project 
on the Efficiency of  Overweight/Obesity Interventions (OECD & WHO) 
The overall aim of the work jointly undertaken by OECD and WHO is to develop an 
economic model to assess the efficiency of interventions to tackle excess 
weight/obesity and associated risk factors (particularly unhealthy diets and lack of 
physical activity) at the population level. The model will be based on a generalized 
cost-effectiveness analysis framework, enhanced by evaluation of the distribution of 
costs and outcomes among different population sub-groups, for example, socio-
economic classes; monetary quantification of the health gain to allow the comparison 
of policies across government departments and finally by the assessment of selected 
externalities. The economic analysis model, as well as the underlying epidemiological 
model, will be designed to be broadly applicable to the largest possible number of 
OECD and EU countries. The modelling methodology will be a continuous time 
microsimulation and the model output will be healthy life expectancy. It considers risk 
factors acting at three different levels (distal, intermediate and proximal risk factors) 
and three diseases (colorectal cancer, stroke and ischemic heart disease).  
   
The IMPACT models (UK) 
The original IMPACT model was a comprehensive CHD model with two modules, 
one for primary prevention that allowed generating incident cases and modelled the 
effect of interventions aimed at upstream and downstream risk factors either at 
population or at the individual level. It could deal with trends in risk factors over time, 
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age and gender. The other module deals with disease treatments, including all 
relevant patient groups (acute coronary syndromes, chronic angina, survivors of 
Myocardial infarction and heart failure), and all the evidence-based treatments.  
 
Successive versions of IMPACT have helped to explain CHD trends in diverse 
populations including England and Wales, Scotland, Ireland, Finland, New Zealand, 
and China (Unal 2004, Ford et al 2007). Projects continue in Canada, Australia, 
Iceland, Poland China, Palestine, Syria, Tunisia, Turkey, the USA and elsewhere.   
 
Published outputs from the IMPACT model now include deaths postponed and also 
life years gained.  Thus in England and Wales between 1981 and 2000, we attributed 
approximately 42% of the decrease in CHD deaths to treatments in individuals 
(including 11% to secondary prevention, 13% to heart failure treatments, and 8% to 
initial myocardial infarction treatments), and 58% to population risk factor 
reductions (principally smoking and to a lesser extent blood pressure and 
cholesterol) (Unal 2004). In spite of adverse trends in obesity, diabetes and activity, 
these modest risk factor reductions gained four times as many life-years as did all 
treatments (Unal 2006). 
 
Having developed and validated a model using data on past trends, it was then 
relatively easy to create and explore a variety of future projections (policy analyses 
using conditional forecasts to illustrate a range of possible interventions). For 
instance, ensuring appropriate treatments reached at least 80% of eligible patients in 
England and Wales could postpone approximately 21,000 CHD deaths annually.  
However, over 50,000 deaths might be avoided or postponed by replicating the 
relatively small reductions in smoking, cholesterol and blood pressure already 
achieved in Scandinavia and the USA (Unal 2005). 
 
Our results have been reassuringly consistent with older studies using diverse 
methods in various countries (Hunink 1997, Bots 1996). Our findings have helped to 
inform policy analyses locally, nationally, and internationally. 
 
Cost-effectiveness and quality of life issues:  Given the spiralling NHS costs for 
CHD, generating reliable cost effectiveness information becomes essential.  Such 
analyses using the IMPACT Model have thus far been limited but interesting (Fidan 
2006). We have shown that cost-effectiveness levels for standard cardiological 
treatments varied by over 100 times.  Aspirin and beta-blockers for secondary 
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prevention of myocardial infarction, angina or heart failure consistently cost less than 
£1000 per life-year-gained (LYG).  Other secondary prevention therapies (such as 
cardiac rehabilitation, ACE inhibitors, or statins), also appeared reasonably cost 
effective.  However, statins as primary prevention were much less cost-effective, 
averaging £27,830 per LYG (Fidan 2006).  These findings remained relatively 
consistent across a wide range of sensitivity analyses.  Results were generally 
consistent with older studies.
 
 
The current IMPACT CHD Model is potentially available to be updated from 2000 to a 
more recent year, depending on data availability. It would then be able to generate a 
series of analyses of past trends and future projections, as in earlier publications. 
 
IMPACT2  (UK) 
Building on the original IMPACT model, the MRC funded a program to extend and 
improve it. The IMPACT2 model will simulate individual CHD patients using event 
driven simulation software developed specifically for the model. The model is built 
with open-source software and will be publicly available. One of the key features of 
this project was a consultation with policy makers at national, regional and local 
levels, in order to explore their views and attitudes towards modelling. This 
information is now guiding both model development and the web-based user 
interface design.  The model is been designed as a generic representation of a 
chronic disease, in order to subsequently allow its extension to the other 
cardiovascular diseases and other chronic disease. 
 
IMPACT2 is a comprehensive CHD model with two modules, one for primary 
prevention that allows generating incident cases and modelling the effect of 
interventions aimed at “upstream” and “downstream” risk factors both at population 
and at the individual level. It could thus deal with trends in risk factors over time, age 
and gender. The other module deals with all relevant patient groups (acute coronary 
syndromes, chronic angina, survivors of myocardial infarction and heart failure), and 
includes all standard evidence based treatments.  
 
The new MRC IMPACT2 CHD Model is being built on the foundations of the original 
IMPACT Model, with input from individuals responsible for the Southampton/LSHTM 
project in the late 1990s.  By end of 2009, a web-based version of IMPACT2  will be 
publicly available.   
More information: http://www.liv.ac.uk/PublicHealth/sc/bua/impact.html  
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USING CVD POLICY MODELS TO ADDRESS CHALLENGING POLICY 
ISSUES  
 
Paradoxically, while CVD mortality has been falling substantially, health policy 
concerns are increasing.  Furthermore, in the USA, UK, and elsewhere CHD 
mortality rates in young adults have recently flattened (Ford 2007, O’Flaherty 2007, 
Allender et al 2007). Moreover, obesity and diabetes prevalence are rapidly rising. 
Meanwhile, diverse health systems are grappling with soaring treatment costs 
exacerbated by the continuing appearance of novel but expensive health 
technologies, such as drug-eluting stents, biological “imabs” and implantable 
defibrillators.  Other important policy questions currently include the potential value 
and cost effectiveness of the “Polypill”, obesity initiatives, diabetes screening, 
smoking cessation schemes, predicting the future need for expensive 
revascularisation procedures given different future scenarios, and comparison of 
diverse combinations of prevention policies targeting prevention at high-risk 
individuals or at the whole population.    
 
The population prevention approach may produce a greater overall impact than 
simply targeting high-risk individuals. However, the impact on inequalities may be 
positive (as in Finland), neutral, or negative. Focused analyses will thus be crucial to 
consider the impact of different interventions on health inequalities.  
 
The next section considers what might be required to develop a comprehensive and 
user-friendly policy model spanning the entire spectrum of CVD.  
 
WHAT NEEDS TO BE INCLUDED IN A LARGE-SCALE MODELLING 
EXERCISE 
 
Key steps  
 Qualitative research is needed to elicit the views of policy makers, NHS 
planners, and other stakeholders (as successfully done in the MRC IMPACT 
CHD project).  
 Critical appraisal of all existing models, and pragmatic decisions about how 
much to use previous work as opposed to starting from afresh. 
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 The identification and critical appraisal of a wide range of data sources covering 
epidemiology, risk factors, patient statistics, treatments, fatal and non-fatal 
outcomes and quality of life. 
 The development of simple models which can be tested with policy makers and 
planners. 
 Iterative development and refinement of more sophisticated models which 
comprehensively cover all key inputs and outputs, and support decision 
making. 
 Increasingly rigorous validation exercises, moving from face validity and internal 
logic checks to comparative validation (with other models) and predictive 
validation (how well does the model estimates compare with subsequent trends  
actually observed in the population) 
 Further valuable scrutiny then comes from peer review during conference 
presentations, workshops and the process of manuscript publication. 
 
 
A) QUALITATIVE RESEARCH TO ELICIT THE VIEWS OF POLICY MAKERS 
AND NHS PLANNERS AND OTHER STAKEHOLDERS  
 
Aim:  To explore attitudes to the use of decision support models for CVD policy 
making and service planning. 
 
Design: Qualitative study using semi-structured interviews. 
 
Participants: Policy and decision makers will need to be purposively sampled from 
the UK National Health Service (NHS) (national, regional and local levels), academia 
and voluntary organizations (as successfully accomplished in the MRC CHD project). 
Analysis: Interviews will need to be transcribed, coded and emergent themes 
identified. Framework analysis will use N-VIVO software. 
 
Such a study would illustrate the potential uses for policy models, the factors that 
improve confidence in them and the general enthusiasm shown by policy makers and 
planners. If existing models are often not being used in practice, then our results 
might help to facilitate the development of a decision support tool that is fit for 
practice.  
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B) A CRITICAL APPRAISAL OF ALL EXISTING MODELS, AND PRAGMATIC 
DECISIONS ABOUT HOW MUCH TO USE PREVIOUS WORK AS 
OPPOSED TO STARTING FROM AFRESH 
 
This will require: 
 a Systematic Review of published work, using Cochrane methodology 
 identification of leading modelling groups, followed by detailed formal 
consultation with these researchers and groups, to elicit comments on our 
completed Systematic Review in Chapter 4 
 followed by convening of a workshop to finalise feedback and hence inform 
subsequent revisions and finalisation of this research programme 
 
C) THE IDENTIFICATION AND CRITICAL APPRAISAL OF A WIDE RANGE 
OF DATA SOURCES COVERING EPIDEMIOLOGY, RISK FACTORS, 
PATIENT STATISTICS, TREATMENTS, FATAL AND NON-FATAL 
OUTCOMES AND QUALITY OF LIFE. 
 
This will build naturally on existing work by the Heartstats team, Unal et al (2004) for 
the England & Wales IMPACT Model, and Ford et al. (2007) for the USA IMPACT 
Model. More detail is available from the relevant websites, which can be accessed 
using HTML addresses in the Appendix 
 
D) THE DEVELOPMENT OF SIMPLE MODELS  
 
 The team will need to develop simple Models, and then provide simple 
webpages & mockups. 
 Then use these simple models to elicit the views of policy makers and 
planners. 
 
E) TESTING SIMPLE MODELS IN CONSULTATION WITH POLICY MAKERS 
AND PLANNERS 
 
Key steps will need to include: 
 Identifying and engaging participants from national, regional and local level, 
including PCTs, PH observatories, NGOs, academia, DH, etc. 
 Showing participants a range of existing web based decision support tool(s). 
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 Enquiring about their previous awareness: What do participants like and 
dislike about the various tools? (Such as time required, relevance of outcome 
measures, concerns about data quality, approaches to tackling health 
inequalities, ability to examine health inequalities in small-areas). 
 
Elicit comments on: 
 specific web based interfaces, specifically perceived Strengths and 
Weaknesses, range of policy  interventions that can be modelled; the 
presentation of results (including issues such as tabulation or graphs, 
confidence intervals and other depictions of estimate ranges and 
uncertainties).  
  CHD or CVD or a wider range of diseases? 
  How intuitive is the particular www interface perceived as to use? 
  Perceptions of the usefulness and applicability of the tool. 
 Are simple and advanced versions needed to meet users’ diverse 
requirements? 
 How can such models best meet policy makers’ expressed needs? 
 Who are the potential users of such policy models?   
 What might such policy models be used for? 
 How much model validation is essential or simply desirable?  
 Choice of specific interventions to model. 
 What balance between local initiatives (such as service commissioning) and 
national initiatives (such as legislation to reduce salt in processed food). 
 
Elicit comments on setting up an analysis, specifically: 
 Ease of use 
 Population Selection 
 Risk Factors to choose singly or in combination 
 Treatments singly or in combination 
 Complex packages of treatments PLUS risk factor reductions. 
 Outcomes quantifies as QALYs, total life expectancy, healthy deaths, death 
rates, DALYs)   
 Cost & Cost-effectiveness 
 Timeframes (for example, over 1 10 or 20 year periods) 
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Elicit comments on presentation of results, specifically: 
 What proportion of health service decision makers are comfortable with the 
graphical presentation of outputs, and how to interpret them 
 How clear and self-explanatory do economic analysis need to be 
 Whether simple figures are more helpful than charts plus explanation 
 How useful it might be to download data and outputs for incorporation into 
reports and presentations 
 
Policy questions to identify the most popular options, for instance: 
 Compare the effects of interventions which tackle risk factors directly against 
each other 
 Compare population strategies of risk factor control versus high risk individual 
approaches (risk assessment, targeting high risk individuals, targeted 
interventions in high risk individuals (treatment of high blood pressure, 
hyperlipidaemia, diabetes and perhaps drug therapy for both obesity and 
smoking) 
 Forecast CHD disease burden on the basis of current risk factors/trends  
 Compare the effects of the increased provision of risk factor interventions with 
the current state of affairs 
 Compare the effects of a set of risk factor interventions and treatments (in 
combination?) with the current state of affairs 
 Test potential effect of new interventions 
 Adding new disease groups 
 Change time horizons of the decisions (from short to short-medium or long 
term) 
 Compare two or more treatments directly against each other  
 Compare the effects of a set of risk factor interventions with a set of 
treatments  
 Compare the effects of the increased provision of treatment with the current 
state of affairs 
 
Elicit comments on Model Usability specifically: 
 Ability to substitute your own data for any of the data used in the model  
 Downloading results for use in other applications  
 Ability to view details of the model’s methodology 
 Availability of pre-run (default) analysis  
 Ability to modify some of the model’s key parameters  
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 Providing confidence intervals around results  
 Ability to inspect the model’s workings/calculations/code  
 Providing user customisable sensitivity analysis  
 Incorporating previous runs in present run  
 Using analyses run by other people  
 Sharing your analysis with other people  
 Ability to inspect model data  
 More detailed step by step scenario set up  
 Improving the model by modifying or adapting the model’s software code  
 
Elicit comments on most useful Potential Outputs, specifically: 
 CHD death rates  
 Years of life lost/gained  
 Life expectancy  
 Numbers of CHD deaths  
 QALYs  
 Probability a strategy is cost-effective  
 Costs  
 Individual disease group prevalence  
 Numbers of all cause deaths  
 Incidence of individual disease groups 
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F) ITERATIVE DEVELOPMENT AND REFINEMENT OF MORE 
SOPHISTICATED MODELS WHICH COMPREHENSIVE COVERING ALL 
KEY INPUTS AND OUTPUTS, AND SUPPORT DECISION MAKING. 
 
All initial versions will then need to be web-based. Model development is an iterative 
process, initially working with crude alpha versions, then more robust beta versions 
which can be shared with a progressively wider group of users. User feedback will be 
crucial to the refinement and development process. Feedback will be structured, 
formalised and facilitated by experienced researchers using a standard approach.  
 
 
G) INCREASINGLY RIGOROUS VALIDATION EXERCISES  
 
I. FACE VALIDITY AND INTERNAL LOGIC CHECKS, THEN 
COMPARATIVE VALIDATION WITH OTHER MODELS  
 
II. PREDICTIVE VALIDATION (HOW WELL DO THE MODEL 
ESTIMATES COMPARE WITH SUBSEQUENT TRENDS 
ACTUALLY OBSERVED IN THE POPULATION?) 
 
For instance, if developing updated versions of IMPACT, the researchers will ideally 
need to compare early and current periods for existing IMPACT data-sets: 
 England & Wales 1980-2000, 2000-2005 
 Scotland 1975-1994, 1995-2005 
 Finland 1982-1997, 1997-2007 
 New Zealand 1982-1993, 1993-2003 
 Ireland 1980-2000, 2000-2005 
Beijing 1982-1999, 1999-2005 
USA 1980-2000, 2000-2005.  
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H) SUSTAINABILITY ISSUES 
 
The web-based model will need to be supported long term on a reliable server. 
Mechanisms and resources for regular reviews and updates of data & methodology 
will be crucial, to ensure the model remains fit for purpose and relevant to the rapidly 
changing policy context. Regular updating of data sources will also be essential. 
 
Use of Open Source Software will help this process, by sharing code with the global 
community, who will then be able to run their own checks, and make further 
refinements. 
 
 
I) FURTHER VALUABLE SCRUTINY THEN COMES FROM PEER REVIEW 
DURING CONFERENCE PRESENTATIONS, WORKSHOPS AND THE 
PROCESS OF  MANUSCRIPT PUBLICATION 
 
In partnership with CVC and BHF, identify and invite peers from UK and abroad.  The 
guest list could include lead researches named in Chapter 4 (other relevant work 
currently taking place). 
 
 
DESIRABLE INTERVENTIONS AND SCENARIOS TO MODEL 
 
The recent IMPACT CHD Policy Makers’ Consultation of over 30 senior policy makers 
and NHS planners was conducted by B Milton, D Taylor-Robinson, F Lloyd Williams, M 
O’Flaherty, J Critchley and S Capewell.    
 
Key findings included: 
 
• Most participants were familiar with the concept of policy modelling, and some had 
carried out, or had commissioned some kind of modelling within their own 
organisations. 
• Some participants had mixed experiences of existing CHD models, and might need 
to be convinced of the value of using an ‘off-the-shelf’ model, as opposed to something 
which had been developed ‘in-house’. 
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• The majority of participants, particularly those involved in decision-making at the local 
and regional levels, welcomed the idea of a CHD Policy Model and could offer clear 
suggestions of how the model could be used to support policy making within their 
organisations. 
• Participants suggested that such a model might be particularly useful for NHS 
commissioning and service planning. 
• Although analysts or intelligence managers within large organisations might use the 
model on a “hands-on” basis, it would be important to progressively enlighten 
senior level staff, in order to enhance the model’s credibility within the organisation. 
• While those with a background in academia expressed concerns about the ways in 
which the validity of model outputs impacted on the quality of data used to build the 
model, those with a health service background were more pragmatic about data 
quality. 
• Factors associated with confidence in policy models included information on 
validation (especially across multiple national contexts), strong academic support, 
consensus around reliability and positive peer-review. 
• Primary prevention concerns included lifestyle (physical activity, smoking, diet, 
obesity and reducing cholesterol) and the social determinants of health. 
• Acute treatment concerns included revascularisation, statins, the treatment of people 
with heart failure, angioplasty, CABGs, primary PCIs and the quality of clinical care. 
• Secondary prevention concerns included risk assessment, statins prescribing, the 
treatment of hypertension and disease registers for people with CHD. 
• Other policy issues identified by participants were the importance of ensuring that the 
policy Model examines impacts on social inequalities in CHD, and the role the model 
might play in enabling participants to meet targets (e.g. PSA targets). 
• Most participants stated that it would be important for the model to address questions 
about the burden of disease, prediction of trends, specific technologies, treatment 
versus preventative strategies, population level interventions, high risk versus whole 
population interventions and cost-effectiveness. 
• Many expressed concerns about spurious precision and false certainty, and stated 
that potential users must be made aware of the limitations and caveats associated 
with model outputs. 
• Participants suggested that potential users would be generally reluctant to take the 
model at face value, but would want to understand the underlying assumptions and 
data sources used.  Users might want different levels of explanation according to their 
level of interest in understanding the model mechanics. 
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• In terms of user issues, participants wanted to know what kind of local area data might 
be available, and also expressed interest in data on outcomes by ethnic group and 
variations associated with socioeconomic deprivation. 
• Models that could show variations in CVD burden for the four countries of the 
UK and regions within them, also enabling inequalities to be highlighted 
 
It would be desirable to use data categorised by region, PCT or Super Output Area 
(SOA) to examine regional variations in risk factors and disease levels.  
 
It would also be feasible to examine deprivation using local data on Risk Factor levels, 
and then weight results using the most recent geographical measures of deprivation, 
such as IMD2004 Deprivation Index & postcode or Super Output Area (SOA). 
 
DELIVERING A MODEL TO PREDICT FUTURE CVD BURDEN 
 
Describing the stages of a large scale CVD modelling programme, with timelines 
The CVC and BHF need a CVD policy model which can provide reasonable estimates 
of trends in Mortality, Incidence, Prevalence, NHS burden, NHS costs and total costs to 
the UK economy. Such estimates would also be valuable for NHS planners at local 
(PCT) and regional (SHA) levels, and for planners and policy makers at national and 
international levels. 
 
Access to such a model could also be used to instantly compare a range of future 
scenarios.   
This would potentially benefit many of the CVC objectives:   
• closer working between central government, local commissioners and the 
voluntary sector in the planning and development of CVD services and policy; 
• strengthening clinical & policy leadership at national & local levels;  
• developing a Cardiovascular Health Strategy for 2010 – 2020 which joins up 
prevention; diagnosis and care throughout the life-course;  
• reducing inequalities;  
• promoting CVD policy and improving standards of care.  
 
A large scale CVD modelling programme is likely to take about five years with 
appropriate resources. The key steps are detailed above, and a realistic timetable is 
shown in the following GANTT chart.  
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GANTT Chart of Proposed Phase 2 CVD Policy Modelling project 
 
# ACTIVITY                  
(month) 
1-
6 
7+ 13+ 19+ 25+ 31+ 37+ 43+ 49+ 55+ 
1 Elicit views of policy 
makers & planners 
xx          
2 Appraisal of existing 
models, 
  x x         
3 Appraising data 
sources 
 xx         
4 Developing simple 
models 
   x xx        
5 Testing simple 
models 
  xx xx       
6 Developing more 
sophisticated 
models 
   xx xx xx     
7 Validation 
exercises- early 
     xx xx    
8 Validation 
exercises- 
predictive 
      xx xx   
9 Peer review & 
dissemination 
  xx  xx   xx xx xx 
10 Sustaining & 
maintaining model 
website 
         xx 
11 Further research &  
development 
      xx   xx 
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DISSEMINATION OF RESULTS VIA HEARTSTATS.ORG 
 
The development of models to predict the future burden of disease is an important 
first step in understanding and planning for the future health care burden. Estimating 
the potential effects of policy and other intervention is also essential to informing 
these decisions.  
 
The data included in a modelling exercise might include mortality rates, morbidity 
rates, hospital admissions and cost data, and policy cost data. Any modelling 
exercise must rely on contemporaneous and historical data to develop predictions of 
the future burden of disease. These estimations necessarily include some degree of 
error because of their theoretical nature.  
 
Apart from the statistical error the data underlying models may behave differently 
over time due to natural variance in disease rates, the impact of planned or 
subsequent public health interventions, treatment advances and other unknown 
factors. For this reason it is important to consider how we might develop a modelling 
approach which is readily updatable as new data become available.  
 
The Coronary Heart Disease Statistics project provides a potentially useful 
framework to develop a rolling programme to provide future data on the burden of 
CVD. For the past 15 years, the CHD statistics project has drawn data from a broad 
network of providers, from routinely collected national data sets and from individual 
small area studies, to update mortality, morbidity, treatment and risk factor statistics 
for coronary heart disease across the United Kingdom.  
 
Within the CHD statistics programme, regularly collected data are used for complex 
analysis of mortality and morbidity rates and to estimate risk factor prevalence. The 
team has progressively developed networks, systems and analysis programmes to 
allow for the regular update of the data presented in CHD statistics compendia. It is 
anticipated that, via this established network of data providers, we will be able to 
continually collect, collate, clean and update models predicting the future burden of 
cardiovascular disease.  
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CONCLUSIONS AND RECOMMENDATIONS 
 
 The burden of CVD is large, costly and increasing.  In future, additional 
resources will therefore be required for CVD prevention and for CVD 
treatments. 
 
 Unless major changes are implemented, the CVD burden will grow during the 
next decade. 
 
 Premature CVD is eminently preventable.  However, the most effective 
interventions may require policy and legislative initiatives to support the 
current attempts to change behaviour in individuals or to medicate them. 
 
 Prediction of CVD trends to 2020 is not straightforward, because some 
factors will increase the burden, while others will decrease it.  
 
 Work to develop and compare methodologies for predicting the future CVD 
burden should therefore be commissioned. 
 
 A separate future project should aim to quantify future service requirements. 
 
 Work is also needed to develop and compare methodologies for evaluating 
the effectiveness of policy and other interventions. 
 
 A comprehensive policy model is therefore required to  
a) Make more reliable future projections and  
b) Compare alternative future strategies. 
 
 Future models should also include analysis of the economic burden of CVD. 
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THE AUTHORS 
 
Prof Simon Capewell has extensive experience in cardiovascular epidemiology and 
patient focused epidemiological research for diverse population groups using multiple 
methodologies.  He qualified from Newcastle University and subsequently worked in 
clinical medicine (general, respiratory and cardiovascular) in Cardiff, Oxford and 
Edinburgh.  He discovered Public Health in the Scottish Office, then moved to 
Glasgow University before appointment to the first Chair of Clinical Epidemiology in 
the University of Liverpool in 1999. 
  
Simon manages a research programme involving various aspects of clinical 
epidemiology, mainly coronary heart disease (CHD).  Outputs include over a hundred 
peer-reviewed papers in the last decade and recent joint funding of some £8million. 
 
Recent work includes an MRC funded programme examining why CHD mortality 
rates have halved in the UK, the USA and elsewhere (how much is due to modern 
cardiological treatments as opposed to risk factor improvements?), and how we 
might help planners and policy makers improve future strategies; and examination of 
trends in CHD and stroke incidence, prevalence and survival (BHF and CSO funded, 
with colleagues in Glasgow and Edinburgh). 
 
Simon is also a Trustee and Director of Research for the Heart of Mersey primary 
prevention programme, which promotes evidence-based healthy food and smoke-
free interventions in the Northwest, the UK and beyond. 
 
Dr Steve Allender has, since 2005, held the post of Senior Researcher with the 
British Heart Foundation Health Promotion Research Group in the Department of 
Public Health at the University of Oxford.  Since joining the Group, Steve has been 
the lead researcher for the Coronary Heart Disease Statistics Project. This post has 
involved the analysis of trends in CHD with work on mortality trends across the 20th 
century and social and demographic trends in risk factor prevalence.  
Steve is also responsible for the www.heartstats.org website, the most 
comprehensive and up-to-date source of statistics on CVD in the UK. It aims to show 
variations and trends in CVD mortality, morbidity, treatment, rehabilitation, prevention 
and risk factors, and is updated on an on-going basis. The site is used by 
researchers internationally to download results and analysis from the Coronary Heart 
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Disease Statistics Project. In 2007 more than 500,000 documents were downloaded 
from the web site. 
Dr Allender was previously a Research Fellow at the University of Oxford Department 
of Public Health (2002-2005), where he was responsible for the Occupational Health 
Services in Higher Education study, a UK wide study of occupational health service 
provision in UK universities. He has also worked on the epidemiological study of 
Porton Down Veterans and has taught research methods, health promotion and 
discourse analysis on a number of courses. 
 
Dr Julia Critchley is Senior Lecturer in Epidemiology in the University of Newcastle. 
An Oxford Health Sciences graduate, Julia gained her D Phil for modelling HIV 
patterns.  She has completed a series of Cochrane systematic reviews and now has 
over 50 peer reviewed papers, including many describing the development and use 
of the IMPACT Policy Model in many different populations. 
 
Dr Ffion Lloyd-Williams trained in Health Education.  Ffion then gained a PhD in 
Health Promotion before working in a variety of research projects. She has been 
Research Manager at Heart of Mersey since 2005, and oversees a variety of 
projects. Ffion has published a number of valuable papers, as well as authoring the 
Systematic Review in the CVD section of the BMJ Public Health website.  Ffion is a 
grant holder on the MRC IMPACT2 project, and leads the Policy Consultation 
component of that study.  
 
Dr Martin O’Flaherty trained in Medicine in Buenos Aires, obtaining the top prize at 
graduation.  He rapidly rose to a consultant physician post.  Martin is currently a 
Research Fellow in the MRC funded IMPACT2 project. 
 
Dr Mike Rayner is Director of the British Heart Foundation Health Promotion 
Research Group, based in the Department of Public Health at the University of 
Oxford.   He founded this research group in 1993 and since then it has established 
an international reputation for research into the burden of cardiovascular disease and 
its prevention.  Since 1993, the Group has been responsible for the British Heart 
Foundation’s Coronary Heart Disease Statistics Project.   Mike has long been an 
active member of various government and non-governmental committees and 
boards. For example, he is currently a member of the Public Health Interventions 
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Advisory Committee for the National Institute for Health and Clinical Excellence and 
the Management Committee of the National Heart Forum 
 
Pete Scarborough joined the British Heart Foundation Health Promotion Research 
Group in 2003, after graduating with a degree in mathematics in 2000. Since 2005, 
Pete has worked as a researcher on the CHD Statistics Project. In addition to the 
annual statistics compendia and supplements, he has contributed to work on 
mortality trends across the 20th century, analyses of the burden of risk factors for 
CHD in the UK, and developing nutrient profile models for the definition of 
*unhealthy* foods and drinks. 
 
Pete is currently working on a DPhil at Oxford University on geographic and 
environmental determinants of the variations of CHD in England. This work involves 
analyses of CHD mortality and hospitalisation rates for all wards in England, and 
utilises measures of area deprivation, climate and the prevalence of risk factors for 
CHD. The latter estimates are generated for wards using a small area modelling 
process known as synthetic estimation.  The DPhil thesis is to be submitted in 
October 2009. 
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APPENDICES  
GLOSSARY 
A  
 
Acute Myocardial infarction:  
The loss of heart muscle as a result of the sudden occlusion of a coronary artery.  
 
Angina:  
Pain or discomfort experienced when the supply of blood to the heart muscle is 
compromised.  
 
Angiotensin-converting enzyme inhibitor: 
A drug used commonly to decrease blood pressure, but that also is used in CHD 
patients with normal blood pressure and in patients with heart failure because of its 
efficacy in blocking the deleterious effect of the activation of the rennin-angiotensin-
aldosterone system in these patients.  
 
Antiplatetelet Drugs:  
Drugs that decrease the ability of platelets to form clots. Examples are aspirin and 
clopidogrel.  
 
Atrial Fibrillation 
The commonest heart rhythm abnormality. Increases the risk of stroke. 
 
Atherosclerosis (or Arteriosclerosis) 
A disease of arteries caused by the progressive deposition of cholesterol resulting in 
a inflammatory response, forming “plaques” lining the interior of the artery and  
leading to its occlusion. 
 
B 
 
Beta blockers: 
An anti-anginal and antihypertensive medication that limits the activity of the 
adrenergic system. It is used in CHD for symptom control in chronic angina even in 
normotensive patients. They have also a small effect in mortality in the setting of 
acute myocardial infarction. Members of this drug family (carvelidol) decreases 
mortality significantly in heart failure patients. 
 
Blood Pressure 
The force exerted by circulating blood on the walls of blood vessels.  The phrase 
blood pressure generally refers to the pressure in the larger arteries (which take 
blood away from the heart). BP most commonly measured by sphygmomanometer. 
BP values are reported in millimetres of mercury (mmHg).  The systolic BP is defined 
as the peak pressure in the arteries,; the diastolic BP is the lowest pressure (at the 
resting phase of the cardiac cycle). Typical values being 120 mmHg systolic and 
80 mmHg diastolic (written as 120/80 mmHg). Large individual variations occur. 
Levels over 140/90 are often described as “high blood pressure”.  
 
Body Mass Index:  
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The relationship between height and weight used to define categories of weight. 
From 18.5 to 25 is considered normal, from 25 to 30 is considered overweight and 
over 30 is considered obesity.  
 
 
C 
 
Cardiovascular diseases:  
Any disease affecting the heart or blood vessels. The term  includes arteriosclerosis, 
coronary artery disease, heart valve disease, arrhythmia, heart failure, hypertension, 
orthostatic hypotension, shock, endocarditis, diseases of the aorta and its branches, 
disorders of the peripheral vascular system, and congenital heart disease. 
 
Cardiovascular risk factors: 
Biological and social traits or behaviours that increase the likelihood of developing or 
dying from cardiovascular disease. The major risk factor for CVD, explaining over 
80% of CVD cases are:  hypertension, smoking, hypercholesterolemia and diabetes 
mellitus. In turn, these risk factor are influenced in part by diet, physical activity, 
obesity and socioeconomic status.  
 
Cardiovascular Risk Scores:  
Mathematical equations derived from cohort studies that quantify the risk of 
developing CVD (dying from CVD or suffering any of the clinical syndromes) based 
on the presence of absence of several CVD risk factors, age and sex. Examples are 
the Framingham Risk Equation, the Scottish ASSIGN score, QRISK, and SCORE.  
 
Carotid disease 
Atherosclerosis affecting one or more carotid arteries supplying blood to the brain. 
Serious narrowing or blockage may produce a stroke.  
 
Cholesterol:  
A fat normally present in the body. Its levels are closely related to the development of 
atherosclerotic obstructive arterial disease, including coronary heart disease, 
cerebrovascular disease and peripheral obstructive disease. It has several 
subfractions, composed by a fat and a protein component: LDL, the main carrying 
cholesterol protein and strongly associated to disease, and HDl, a protein fraction 
involved in the breakdown and removal of cholesterol from arterial walls, and thus 
decreasing disease risk.  
 
Concurrent validity:   
This aspect of validity is usually performed by putting similar questions to different 
models with different methodologies, and compare its outputs Congenital Heart 
Disease:  
 
Competing Causes or Risk:  
risk that can occur that are not the specific disease outcome being analysed. For 
example, CHD patients may die from CHD or from other, non CHD related causes.  
 
Congenital heart disease is a heart condition resulting from an abnormality in heart 
structure or function that is present at birth. 
 
Coronary angiogram:  
A radiological diagnostic procedure that involves the placement of a cathether in the 
coronary arterial system, in order to asses the extent of atherosclerotic occlusive 
disease, ventricular and valve function.  
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Coronary Artery By Pass Grafting:  
A major surgical procedure that allows the restoration of coronary blood flow to the 
myocardium affected by a coronary artery obstruction of varying degree.  
 
Coronary heart disease:  
is the result of the obstruction of the coronary arteries of the heart, usually caused by 
atherosclerosis. Its clinical manifestations are sudden death, acute coronary 
syndromes (acute myocardial infarction and unstable angina) and chronic angina.  
 
D 
 
Diabetes:  
A disease of carbohydrate metabolism caused by impaired function of insulin or by its 
absence. Patients experience an increase in risk of developing vascular 
complications in large vessels (macrovascular complications), including CHD, Stroke. 
They also are at risk of developing retinal diseases leading to blindness and kidney 
failure (microvascular complications).  Diabetes is usually defined as a fasting blood 
glucose above 7.0 mmol/l 
 
Discrete Event Simulation: 
A cohort simulation method that involves simulating individuals moving through 
different pathways that represent a disease or a group of diseases. The simulation is 
driven by the occurrence of events in time, that create milestones in each individual 
history. 
 
E 
 
Embolism 
Thrombi (blood clots) which form in the blood circulation. heart, especially in patients 
with Atrial Fibrillation. These thrombi can then travel through the circulation and 
cause an embolism, ie obstruct blood flow in a crucial artery, for instance causing a 
stroke or a heart attack.  
 
F 
 
Face Validity:  
In modelling, face validity means the way the disease processes being modelled are 
view as realistic by experts.  
 
G 
 
Glucose intolerance:  
An abnormal glucose level, particularly after a meal that is not high enough to be 
classified as diabetes, but associated to the development of disease.  
 
H 
 
Health Impact Assessment:  
An analytical strategy that offers an analysis of the potential consequences of any 
pending decision on the health of a population.  
 
Heart Failure:  
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A syndrome characterized by shortness of breath, decreased functional capacity, 
fluid retention and severely reduced life expectancy. About half of the cases of heart 
failure can be attributed to the consequences of coronary heart disease.  
 
 
Hypercholesterolaemia: 
A condition caused by elevated levels of cholesterol or its subfractions. This greatly 
increase he risk of coronary heart disease, stroke, peripheral heart disease and 
kidney failure.  
 
Hypertension:  
A condition caused by elevated blood pressure, increasing the risk of coronary heart 
disease, stroke, peripheral heart disease and kidney failure.  
 
L 
 
Lag times:  
In CVD modelling, we use this term to refer to the fact that the changes in CHD 
outcomes is not instantaneous following a change in a risk factor.  
 
M 
 
Markov Models:  
The disease process is here represented as a series of discrete disease states. A 
proportion of a cohort of individuals will move across the states according to a 
transition probability.  
 
Model comprehensiveness:  
In epidemiological modelling, the extent to what all determinants of incidence and 
treatments of established diseases are contemplated in the model.  
 
Montecarlo Simulation:  
A statistical procedure used to draw from a probability distribution a list of values to 
be used as inputs in a model, usually as part of a probabilistic sensitivity analysis.  
 
Multi-state life tables models:  
Basically Markov models, they use a lifetable approach to estimate outcomes.  
 
O 
 
Obesity:  
a condition caused by the accumulation of fat in the body. It is usually defined as a 
body mass index of 30 or more. But obesity and overweight are related to adverse 
heart outcomes, including hypertension, diabetes, CVD and cancer.  
 
P 
 
Percutaneous Coronary Intervention (PCI):  
an invasive therapeutic procedure with the aim of opening an occluded coronary 
artery, usually caused by a progressive occluding or acutely complicated coronary 
artery atherosclerotic plaque. When performed in the setting of an acute myocardial 
infarction, it is called “primary percutaneous coronary intervention”.  
 
Peripheral arterial disease:   
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A number of diseases are categorized in this group, but frequently it refers to the 
progressive occlusion of arteries in the limbs that results in exertion related limb pain 
or  limb loss or the development of dilatation and rupture of major arteries, usually 
the aorta.  
 
Policy model:  
Any mathematical decision support tool that may help at a population level to explain 
or predict the outcome of interventions 
 
Prevalence:  
the number of existing cases of a disease in a population in a point in time, usually 
expressed as a rate (number of existing cases/population at risk) 
Incidence: The number of new cases of a disease in a population in a period of time, 
usually expressed as a rate (number of new cases/person years at risk) 
 
Primary Prevention:  
A set of activities aimed to control disease by  modifying the levels of disease risk 
factors, targeting the individual, the population of both.  
 
Primordial prevention:  
Activities targeted to delay or altogether prevent the development of abnormal levels 
of risk factors.  
 
Probabilistic Sensitivity Analysis:  
A sensitivity analysis method that takes into account the statistical distribution of the 
parameters in the model to try to represent and quantify the resulting uncertainty in 
model outputs.  
 
R 
 
Rate standardization:  
A statistical procedure used to adjust mortality rates by several factors. It is usually 
used to compare rates across populations or in time for the same population, taking 
into account differences in the age and sex structure.  
 
S 
Secondary Prevention:  
A set of activities aimed to reduce the risk of dying or of development disease related 
complications, involving the provision of acute care and chronic care, management of 
risk factors and rehabilitation. 
 
Sensitivity Analysis:  
an analytical approach used in modelling to take into account the different sources of 
uncertainty and its effect on model outcomes, inherent to any modelling exercise.  
 
Statins:  
a family of drugs that block a key enzyme in the metabolism of cholesterol, lowering 
total cholesterol and LDL levels.  
Stroke:  
The sudden loss of cerebral function. It has two main types: ischemic and 
hemorrhagic. The first is usually the result of occlusion of extracranial or intracranial 
cerebral arteries (by occluding atheromatous plaques or by cardiac emboli), while 
hemorrhagic strokes may be the results of hypertensive cerebrovascular diseases or 
the rupture of arterial aneurism of arteriovenous malformations.  
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T 
 
Transition probability:  
the probability of moving between states in a Markov multistate model.  
 
U 
 
Unstable Angina:  
A clinical syndrome characterized by signs and symptoms of ongoing myocardial 
ischemia without evidence of myocardial loss, as measured by biochemical markers.  
 
V 
 
Validation:  
A process through a model increases its value as a tool, by ascertaining that the 
model does what is intended to do. There are several aspects of validity that can be 
addressed: face validity, concurrent validity, predictive validity. 
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USEFUL WEBSITES 
Heart of Mersey: www.heartofmersey.org.uk 
Heartstats: www.heartstats.org 
IMPACT: www.liv.ac.uk/PublicHealth/sc/bua/impact.html 
 
DYNAMO: www.dynamo-hia.eu/object_class/dyhia_aims.html 
 
POHEM: www.statcan.ca/english/spsd/Pohem.htm 
 
English IMPACT website: http://www.liv.ac.uk/PublicHealth/sc/bua/impact.html 
 
USA IMPACT NEJM article website: http://dx.doi.org/10.1056/NEJMsa053935 
 
 
 
 
About the Cardio &Vascular Coalition
The Cardio and Vascular Coalition (CVC) is a
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with an interest in promoting and protecting
cardiovascular health in England.
The CVC is committed to working with and
influencing central and local government,
health and social care commissioners, service
planners and policy makers to ensure that
cardiovascular health is high on their agendas.
In 2008-09 the CVC is working to highlight the
need for a comprehensive Cardiovascular
Health Strategy for 2010 – 2020.
